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Ubiquitination	controls	the	stability	of	most	cellular	proteins,	and	its	deregulation	
contributes	to	human	diseases	including	cancer.	Deubiquitinases	(DUBs)	remove	ubiquitin	
from	proteins,	and	their	inhibition	can	induce	degradation	of	select	proteins,	potentially	
including	otherwise	‘undruggable’	targets.	For	example,	inhibition	of	ubiquitin-specific	
protease	7	(USP7)	results	in	degradation	of	the	oncogenic	E3	ligase	MDM2,	leading	to	re-
activation	of	the	tumour	suppressor	p53	in	various	cancers.	We	here	present	two	
compounds,	FT671	and	FT827,	that	inhibit	USP7	with	high	affinity	and	specificity	in	vitro	
and	in	cells.	Co-crystal	structures	reveal	that	both	compounds	target	a	dynamic	pocket	
near	the	catalytic	centre	of	the	auto-inhibited	apo-form	of	USP7,	which	differs	from	other	
USP	DUBs.	Consistent	with	USP7	target	engagement	in	cells,	FT671	destabilises	USP7	
substrates	including	MDM2,	elevates	p53	and	results	in	transcription	of	p53	target	genes,	
induction	of	the	tumour	suppressor	p21,	and	tumour	growth	inhibition	in	vivo.		
	
The	 transcription	 factor	p53	 is	an	 important	 tumour	 suppressor	 that	 is	 lost	or	mutated	 in	
>50%	of	human	cancers,	and	multiple	oncogenic	mechanisms	lead	to	its	degradation	by	the	
proteasome1,2.	 Consequently,	 stabilisation	 and	 (re-)activation	 of	 p53	 is	 a	 key	 aim	 of	
pharmaceutical	 research.	 One	 strategy	 focuses	 on	 targeting	 the	 oncogenic	 ubiquitin	 E3	
ligase	MDM2,	which	binds,	ubiquitinates,	and	destabilises	p532,3.	 Inhibitors	such	as	Nutlins	
prevent	the	MDM2-p53	interaction	and	p53	loss,	with	encouraging	pre-clinical	results2.			
	
MDM2	is	protected	from	autoubiquitination	and	degradation	by	the	deubiquitinase	USP74,5,	
and	genetic	or	chemical	interference	with	USP7	function	destabilises	MDM2	and	elevates	
p53	levels4-6.	Small	molecule	inhibitors	have	been	reported	that	target	USP7	with	a	
relatively	narrow	dynamic	range	(20-40	µM	for	P22077/P5091	and	25-50	µM	for	
HBX41108).	While	they	also	inhibit	related	and	unrelated	enzymes7-9,	treatment	with	
P22077/P5091	leads	to	MDM2	destabilisation	and	p53	stabilisation8,10-14,	resulting	in	
tumour	cell	death	in	vivo15-17.	P5091	is	able	to	overcome	resistance	to	proteasome	inhibition	
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by	bortezomib	in	multiple	myeloma	cells	that	overexpress	USP712.	Consequently,	these	
compounds	reduce	medulloblastoma,	colorectal	and	lung	tumour	growth	in	mice13,18,19,	but	
it	is	unclear	whether	these	effects	are	solely	attributable	to	USP7	target	modulation.	
	
Discovery	of	specific	USP7	inhibitors	
We	identified	USP7	inhibitors	using	a	ubiquitin-rhodamine	assay20,	screening	the	inhibitory	
potential	of	a	diverse	collection	of	~500K	compounds	available	at	FORMA	Therapeutics21.	
From	this,	we	identified	several	primary	hits	that	were	further	validated	for	direct	USP7	
binding	by	biophysical	techniques	such	as	surface	plasmon	resonance	(SPR).		Optimisation	
of	the	original	hits	with	respect	to	activity	and	physicochemical	properties	resulted	in	the	
prioritisation	of	a	pyrazolo[3,4-d]pyrimidin-4-one-piperidine	(PyrzPPip)	series21.	Within	the	
series,	we	identified	a	covalent	inhibitor,	FT827,	and	a	non-covalent	inhibitor,	FT671	(Fig.	
1a).	FT671	and	FT827	bind	to	the	USP7	catalytic	domain	(USP7CD;	residues	208-560,	
Extended	Data	Fig.	1a)	with	apparent	Kd	values	of	65	(45-92)	nM	and	7.8	(5.9-10.2)	µM,	
respectively	(Extended	Data	Fig.	1b).	FT671	inhibits	USP7	with	IC50	values	of	52	(29-94)	nM	
(USP7CD)	and	69	(39-120)	nM	(USP7C-term,	residues	208-1102)	(Extended	Data	Fig.	1c).	FT827	
features	a	vinylsulfonamide	moiety	that	covalently	modifies	the	catalytic	Cys223	of	USP7	
and	inhibits	the	enzyme	with	a	kinact/KI	of	66	±	25	M-1s-1	(Fig.	1a,	Extended	Data	Fig.	1d,	
Methods).	FT671	and	FT827	exclusively	inhibit	USP7	in	a	panel	of	38	DUBs	from	diverse	
families	(Fig.	1b,	Extended	Data	Table	1).	We	also	tested	FT671	against	USP47	and	USP10,	
two	enzymes	inhibited	by	P5091/P220777,9,	but	found	no	effect	on	their	activity	(Extended	
Data	Table	1).		
	
To	test	compound	specificity	in	a	cellular	context,	we	incubated	FT827	or	FT671	with	either	
crude	cell	extracts	or	with	intact	MCF7	breast	cancer	cells,	followed	by	incubation	with	the	
ubiquitin	active	site	suicide	probe	HA-UbC2Br22	(Fig.	1c,	d,	Extended	Data	Fig.	2a,	see	
Methods).	Both	compounds	inhibited	USP7	probe	reactivity	with	IC50s	of	~0.1-2	µM,	
confirming	10	to	100-fold	higher	potency	as	compared	to	P22077	(Extended	Data	Fig.	2g).	
Immunoblotting	for	the	HA-tag	qualitatively	indicated	that	no	other	DUB	was	affected	
(Extended	Data	Fig.	2),	which	was	confirmed	by	mass-spectrometry	(MS)	experiments7,23.	
For	this,	HA-UbC2Br-modified	DUBs	were	immunoprecipitated	by	anti-HA	antibody,	and	out	
of	36	endogenous	DUBs	identified,	22	were	of	sufficient	abundance	to	enable	quantitative	
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measurements	(Fig.	1e,	f,	Extended	Data	Fig.	2a,f).	FT671	or	FT827	only	affected	USP7,	but	
not	other	DUBs	including	USP47	and	USP10	(Fig.	1e,	f,	Supplementary	Tables	1,	2).	Hence,	
FT827	and	FT671	are	bona	fide	USP7-specific	inhibitors.	
	
Structures	of	USP7-inhibitor	complexes		
To	understand	the	mechanism	and	specificity	of	USP7	inhibitors,	USP7CD	crystals	were	
soaked	with	FT671	and	FT827	and	co-crystal	structures	were	determined	to	2.35	and	2.33	Å	
resolution,	respectively	(Fig.	2a,	Extended	Data	Fig.	3,	Extended	Data	Table	2).	The	USP7	
catalytic	domains	adopt	the	well-characterised	hand-like	structure	with	Thumb,	Fingers,	and	
Palm	subdomains24	(Fig.	2a),	and	compounds	bind	in	the	Thumb-Palm	cleft	that	guides	the	
ubiquitin	C-terminus	into	the	active	site	(Fig.	2a-e).	Identical	interactions	occur	between	the	
PyrzPPip	scaffold	and	Asp295,	Val296	(backbone),	Gln297	from	the	Thumb	subdomain,	
Phe409	(backbone)	and	Tyr465	of	the	Palm	subdomain	(Fig.	2d,	e,	Extended	Data	Fig.	4).	
The	PyrzPPip	scaffold	of	non-covalent	FT671	(Fig.	2d)	is	extended	towards	the	Fingers	
subdomain	by	a	para-fluorophenyl	group,	and	towards	the	catalytic	centre	by	a	3-
fluoropyrazole	group	that	packs	against	the	piperidine	group	and	resides	4.7	Å	from	the	
thiol	side	chain	of	catalytic	Cys223.	The	covalent	compound	FT827	(Fig.	2e)	is	not	extended	
towards	the	Fingers	subdomain,	but	is	elongated	towards	the	catalytic	centre,	enabling	the	
vinylsulfonamide	moiety	to	form	a	covalent	bond	with	Cys223.		
	
The	inhibitor	structures	highlight	the	plasticity	of	USP7,	which	is	known	to	undergo	
significant	structural	changes	upon	ubiquitin	binding24.	The	catalytic	Cys223	moves	from	an	
incompetent	(apo	USP7)	to	a	catalytically	competent	conformation	in	complex	with	e.g.	
ubiquitin	aldehyde	(UbAl)	(Fig.	2b,	c).	Further	changes	in	the	ubiquitin	binding	channel,	in	
particular	rotation	of	a	Phe	side	chain	(Phe409	in	USP7,	Fig.	2b-f),	open	a	hydrophobic	
pocket	that	is	occupied	by	ubiquitin	Leu73	24	(Fig.	2c).	Similar	conformations	of	the	Phe409-
equivalent	residue	are	observed	in	all	published	USP	structures	(see	below,	Fig.	2g).		
	
FT671	and	FT827	bind	to	the	inactive	apo	state	of	USP7,	which	is	reflected	by	lower	RMSD	
values	of	compound-bound	vs.	USP7-apo	(0.4	Å)	as	compared	to	compound-bound	vs.	
USP7~UbAl	structures	(0.8-1	Å,	a	~	indicates	a	covalent	complex)	(Fig.	2b-e,	3a).	In	the	
USP7~FT827	structure,	the	compound	has	modified	the	incompetent	conformation	of	
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Cys223	despite	the	lack	of	the	deprotonating	activity	of	His464,	and	Phe409	is	in	the	apo	
conformation	(Fig.	2e,	f).	Even	more	striking	is	the	Phe409	conformation	in	USP7-FT671,	in	
which	the	compound	has	expelled	Phe409	to	a	solvent	exposed	conformation	not	observed	
previously	(Fig.	2d,	f).	This	highlights	surprising	plasticity	in	USP	domains	whereby	one	of	
our	compounds	occupies	a	pocket	not	present	in	either	the	apo-	or	in	ubiquitin-bound	USP7	
structures.	Together,	the	structures	explain	the	high	affinity	binding	properties	of	FT671	and	
FT827,	and	the	location	in	the	ubiquitin	binding	site	explains	their	mechanism	of	action	as	
ubiquitin-competitive	small	molecules.		
	
Molecular	basis	for	compound	specificity	
The	structures	further	reveal	the	molecular	basis	for	compound	specificity	towards	USP7	
(Fig.	3,	Extended	Data	Fig.	5).	USP7	residues	that	mediate	interactions	to	the	inhibitors	
(Asp295,	Val296,	Gln297,	Phe409,	Tyr465)	are	highly	conserved	in	the	majority	of	USP	
enzymes25,	and	sequence	differences	in	the	compound	binding	site	alone	do	not	explain	
compound	specificity.	Instead,	the	reason	for	the	specificity	lies	in	unique	structural	
features	of	the	USP7	Thumb	subdomain,	which	harbours	an	allosteric	regulatory	interaction	
site	known	as	the	switching	loop	(Fig.	3a).	This	loop,	located	between	helices	α4	and	α5	
(residues	283-295),	allows	sufficient	space	for	compound	binding	in	apo	USP7.	Importantly,	
the	switching	loop	changes	upon	ubiquitin	binding24,	when	a	helical	turn	straightens	and	
complements	the	extended	ubiquitin	C-terminus	(Fig.	3a,	2c).	In	the	ubiquitin-bound	
conformation,	new	hydrogen	bonds	between	Tyr465	and	Tyr514	of	the	Palm,	and	Asp295-
Val296	of	the	switching	loop	are	formed,	which	rigidifies	the	ubiquitin	binding	channel.	
These	Palm-Tyr:Thumb	contacts	are	highly	conserved,	and	importantly,	are	already	formed	
in	all	other	apo	USP	structures	reported	to	date	(Extended	Data	Fig.	5b),	i.e.	in	the	absence	
of	ubiquitin.	Indeed,	pre-formed	Palm-Tyr:Thumb	contacts	and	competent	catalytic	triad	
residues	appear	to	poise	other	USPs	for	ubiquitin	binding	(Extended	Data	Fig.	5b).		
	
Here,	USP7	is	distinct:	the	switching	loop	conformation	in	apo	USP7	disallows	a	Tyr465	
Thumb	interaction	(distance	7.9	Å),	and	the	rotated	Tyr465	side	chain	is	free	to	form	a	
hydrogen	bond	with	the	compound	(Fig.	2b,	d,	e,	3a,	c,	Extended	Data	Fig.	4,	5).	The	
unrestrained	conformation	of	Tyr465	allows	nearby	Tyr514	to	sit	flat	in	the	ubiquitin	binding	
channel	(Fig.	3c,	d),	and,	in	contrast	to	other	USPs,	this	residue	does	not	interact	with	the	
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switching	loop.	Both	Tyr	conformations	create	space	for	compound	binding.	In	all	other	USP	
structures,	equivalent	Tyr	residues	point	into	the	ubiquitin	binding	channel,	which	would	
prevent	interactions	with	our	compounds	(Fig.	3c-e,	Extended	Data	Fig.	5b).	Together,	
unique	positions	of	Tyr465	and	Tyr514	in	the	ubiquitin	binding	channel,	enabled	by	a	unique	
conformation	of	the	switching	loop	in	apo	USP7,	allow	FT671	and	FT827	to	specifically	
target	USP7.		
	
Characterisation	of	compound	binding	
Compound	binding	modes	were	tested	by	mutational	analysis,	with	the	aim	to	identify	
compound	resistant	USP7	mutants.	This	was	challenging,	since	most	residues	involved	in	
compound	binding	are	also	involved	in	ubiquitin	binding	and/or	catalysis,	and	mutations	
had	detrimental	effects	on	USP7	function.	For	example,	mutation	of	Tyr465,	which	forms	a	
hydrogen	bond	with	compound	(Fig.	2d-e,	Fig.	3c-e,	see	above),	abrogated	compound	
binding	without	affecting	ubiquitin	interaction	as	assessed	by	SPR	(Extended	Data	Fig.	6a-d).	
However,	while	folded	(Extended	Data	Fig.	6e),	the	USP7CD	Y465N	mutant	showed	a	greatly	
reduced	catalytic	efficiency	(kcat)	(Fig.	3f,	Extended	Data	Fig.	6f),	rendering	it	less	useful	for	
further	analysis.	Interestingly,	USP7	Q297A,	which	removes	the	hydrogen	bond	with	the	
compound’s	pyrazolo-pyrimidin-4-one	group	(Fig.	3e),	retains	ubiquitin	binding	and	some	
catalytic	activity	(Fig.	3f,	Extended	Data	Fig.	6c,	6f),	but	compound	binding	and	inhibition	is	
abrogated	(Fig.	3g,	Extended	Data	Fig.	6a-b,	6d).	Finally,	we	examined	the	importance	of	
the	switching	loop	directly	by	mutating	Phe291,	which	does	not	contact	the	compounds,	but	
is	important	for	the	integrity	of	the	switching	loop	in	apo	USP7	(Fig.	3e).	Also	USP7CD	F291N	
showed	strongly	reduced	compound	binding	and	inhibition	(Fig.	3g,	Extended	Data	Fig.	6a,	
6b),	but,	in	contrast	to	the	other	mutants,	and	in	agreement	with	previous	work26,	showed	
improved	ubiquitin	affinity	and	ubiquitin-rhodamine	activity	(Fig.	3f,	Extended	Data	Fig.	6c,	
d,	f).	This	supports	the	notion	that	mutations	in	Phe291	shift	the	equilibrium	towards	an	
active	USP7	conformation26.	The	switching	loop	is	a	point	of	intrinsic	allosteric	regulation	of	
USP7	via	its	own	C-terminal	region	and	activating	proteins	such	as	GMPS26-2930	(Extended	
Data	Fig.	6g).	Importantly,	FT671	binds	and	inhibits	both	USP7CD	and	the	more	active	USP7C-
term	with	identical	parameters	in	vitro	(Extended	Data	Fig.	1c),	and	both	compounds	engage	
endogenous	USP7	in	cells	(Fig.	1c-f,	Extended	Data	Fig.	2).	This	indicates	that	USP7	cycles	
through	apo-like	structures	that	can	be	targeted	by	our	compounds.		
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Biological	activity	of	FT671	
Cell	lines	derived	from	colorectal	carcinoma	(HCT116)	or	bone	osteosarcoma	(U2OS)	
respond	to	USP7	knock-down	with	p53	stabilisation	and	p21	induction,	leading	to	growth	
arrest	and	apoptosis	(Extended	Data	Fig.	7a,	b).	Similarly,	FT671	increases	p53	protein	levels	
in	these	cell	lines	(Fig.	4a,	b),	leading	to	induction	of	p53	target	genes	including	
BBC3/PUMA,	CDKN1A/p21,	RPS27L/S27L	and	MDM2	(Fig.	4c,	Extended	Data	Fig.	7c).	The	
increase	in	p53	correlates	with	increased	MDM2	degradation,	which	is	initially	balanced	by	
p53-induced	MDM2	expression31,32	but	impacts	on	MDM2	protein	levels	after	prolonged	
compound	treatment	(Fig.	4a,	Extended	Data	Fig.	7d).	Overall,	these	effects	are	similar	to	
what	has	been	observed	with	less	specific	compounds12,13,18,19.	To	verify	that	the	effects	on	
p53	arises	from	USP7	inhibition,	we	exploited	compound	resistant	mutants	(Fig.	3e-g).	
Stable	HCT116	cell	lines	expressing	a	single	additional	copy	of	USP7	WT	or	USP7	mutants	via	
a	Flp-In	TRex	system,	showed	identical	p53	induction	in	control	and	USP7	WT	expressing	
cells	upon	FT671	treatment,	but	failed	to	induce	p53	when	USP7	Q297A	or	USP7	F291N	
were	expressed	(Fig.	4d,	Extended	Data	Fig.	7e).		
Numerous	substrates	of	USP7	have	been	reported,	and	may	be	modulated	by	USP7	
inhibition33-35.	Indeed,	FT671	led	to	the	degradation	of	N-Myc	and	upregulation	of	p53	in	the	
neuroblastoma	cell	line	IMR-32,	consistent	with	a	previous	report33	(Extended	Data	Fig.	7f).	
USP7	is	also	part	of	a	demethylase	complex,	and	regulates	the	E3	ligase	UHRF1	and	the	DNA	
methylase	DNMT134,35.	FT671	leads	to	degradation	of	both	proteins	(Extended	Data	Fig.	
7g,h),	showing	that	their	regulation	depends	on	USP7	activity.	As	such,	USP7	inhibitors	
appear	suitable	to	study	a	variety	of	other	biological	contexts.		
	
Physiological	responses	to	FT671	
As	for	other	cell	lines,	FT671	also	stabilises	p53	in	the	MM.1S	multiple	myeloma	cell	line	
(Extended	Data	Fig.	8a),	which	correlates	with	increased	MDM2	ubiquitination	(Extended	
Data	Fig.	8b)	and	leads	to	expression	of	p53	target	genes	(Extended	Data	Fig.	8c,	d).	FT671	
blocks	proliferation	of	MM.1S	cells	with	an	IC50	of	33	nM	as	determined	by	CellTiter-Glo	
assay	(Fig.	5a).	To	test	FT671	effects	on	the	p53-MDM2	axis	in	vivo,	we	utilised	a	MM.1S	
xenograft	mouse	model	in	which	NOD-SCID	mice	were	implanted	with	MM.1S	cells	and	
randomized	into	different	treatment	groups.	For	pharmacodynamics	studies,	compound	
was	administered	once-a-day	(QD)	at	25	mg	kg-1,	75	mg	kg-1	or	200	mg	kg-1	via	oral	gavage.	
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Individual	mice	were	sacrificed	at	different	time	points,	and	compound	effects	on	p53	were	
monitored	(Fig.	5b,	Extended	Data	Fig.	8e).	Mirroring	the	studies	in	cell	lines	(Fig.	4,	
Extended	Data	Fig.	8a-d),	p53	stabilisation	in	tumour	tissue	was	observed	shortly	after	a	
single	dose	of	FT671	(Fig.	5b).	After	24	h,	p53	levels	have	returned	to	those	of	the	vehicle	
treated	control	(Fig.	5b,	Extended	Data	Fig.	8e).		
The	in	vivo	anti-tumour	growth	activity	of	FT671	was	tested	in	the	MM.1S	xenograft	model	
after	daily	dosing	via	oral	gavage	at	100	mg	kg-1	and	200	mg	kg-1.	Treatment	of	mice	with	
FT671	led	to	significant	dose-dependent	tumour	growth	inhibition	(Fig.	5c).	FT671	was	well	
tolerated	even	at	high	doses,	and	no	significant	weight	loss	or	cachexia	was	observed	during	
the	study	(Fig.	5d).			
	
Conclusion	
Together,	our	identification	of	highly	specific	USP7	inhibitors	including	the	nanomolar-
potency,	non-covalent	compound	FT671,	shows	that	USPs	are	tractable	drug	targets	for	
cancer	and	also	other	diseases36,37.	The	underlying	concepts	of	targeting	otherwise	
intractable,	‘undruggable’	proteins	by	modulating	their	half-life,	is	an	important	emerging	
concept	in	drug	discovery38,39.	It	has	been	unclear	whether	the	structurally	highly	similar	
USP	DUBs	would	be	amenable	to	the	discovery	of	specific	small	molecules.	We	here	show	
not	only	that	this	is	possible,	but	also	that	the	remarkably	dynamic	USP	catalytic	domain	
reveals	interaction	sites	for	small	molecules	that	could	not	have	been	predicted	from	
available	structures.	The	generation	of	similarly	selective	inhibitors	for	other	family	
members	will	unveil	the	full	therapeutic	potential	of	DUB	inhibitors.		
	
	 	
	 9	
Acknowledgements	
We	thank	Diamond	Light	Source	for	access	to	beamlines	I03	and	I04.	We	thank	Susan	M.	
Boyd	for	providing	Extended	Data	Fig.	4,	and	Saosan	Suhrawardy,	Victoria	Smith	and	Zhanru	
Yu	for	help	with	experiments.	Work	in	the	DK	lab	is	supported	by	the	Medical	Research	
Council	[U105192732],	the	European	Research	Council	[309756],	and	the	Lister	Institute	for	
Preventive	Medicine.	Work	in	the	BMK	lab	was	supported	by	a	John	Fell	Fund	133/075,	the	
Wellcome	Trust	(097813/Z/11/Z)	and	the	Engineering	and	Physical	Sciences	Research	
Council	(EP/N034295/1).	L.S.	received	a	stipend	from	North	West	Cancer	Research.		
	
Author	contributions:	
This	study	was	directed	by	T.R.H.,	S.K.,	S.I.,	C.J.D.,	K.W.B.,	J.A.E.,	S.B.M.,	T.M.R.,	M.S.,	S.U.,	
M.J.C.,	B.M.K.	and	D.K..	S.I.	led	the	chemistry	supported	by	C.J.D.	and	K.W.B..	Synthetic	
routes	and	approaches	were	devised	and	carried	out	by	B.C.F.,	A.C.T.,	A.J.B.	with	
computational	chemistry	support	by	D.R.L.,	J.A.C.,	M.W.,	C.L.M.	and	A.V.T..	USP7	
biochemical	assays	were	developed	and	performed	by	C.L.M,	A.C.L.M.,	L.M.T.,	C.A	and	F.S..	
USP10	and	USP47	assays	were	performed	by	C.L.M..	A.P-F.	carried	out	compound	specificity	
studies	and	quantitative	mass	spectrometry	using	methods	established	by	T.M.C.,	H.C.	and	
J.F.M.	under	guidance	of	B.M.K.	Biophysical	studies	were	performed	by;	surface	plasmon	
resonance:	A.C.L.M.	and	L.M.T.;	circular	dichroism:	L.M.T.;	kinact/KI:	A.C.L.M.	using	methods	
established	by	F.S..	A.P.T.	and	W.W.K.	performed	the	structural	studies	and	analysis	with	
input	from	D.R.L.,	A.V.T.,	N.J.E.,	M.G.	and	D.K..	M.S.P.	and	L.M.T.	produced	protein	for	all	
experiments	with	input	from	L.M.D.S..	Biological	studies	were	designed	and	performed	by	
C.H.	with	the	help	of	L.S.	under	guidance	of	S.U.	and	M.J.C.,	and	carried	out	independently	
by	L.S.,	C.G.M.,	E.C.T.,	S.M.B.,	J.L.,	M.W.,	M.S.	under	guidance	of	S.I.	and	S.K..	V.V.Z.	carried	
out	antiproliferative	assay	in	MM.1S	cells.	J.L.	and	E.W.	designed	and	supervised	in	vivo	
animal	studies	performed	at	Pharmaron,	China.	D.K.,	B.M.K.,	A.P.T.	and	S.I.	wrote	the	
manuscript,	and	all	authors	commented	on	the	text.	
	
Author	information	
Reprints	and	permissions	information	is	available	at	www.nature.com/reprints.		
A.P.T.,	W.W.K.,	A.C.L.M.,	L.M.T.,	N.J.E.,	C.A.,	F.S.,	M.S.P.,	T.M.R.,	L.M.D.S.,	S.B.M.,	T.R.H.	are	
employees	of	CRUK	Therapeutic	Discovery	Laboratories.	S.I.,	E.C.T.,	S.M.B.,	D.R.L.,	J.A.C.,	
	 10	
A.V.T.,	J.L.,	E.W.,	B.C.F.,	V.V.Z.,	A.C.T.,	A.J.B.,	M.W.,	C.L.M.,	C.G.M.,	M.S.,	J.A.E.,	K.W.B.,	C.J.D.	
S.K.	are	employees	of	FORMA	Therapeutics.	This	work	was	performed	by	the	DUB	Alliance	
and	funded	by	FORMA	Therapeutics.	
Correspondence	and	requests	for	material	should	be	addressed	to	dk@mrc-lmb.cam.ac.uk	
or	benedikt.kessler@ndm.ox.ac.uk.	Compound	requests	should	be	addressed	to	
sioannidis@formatherapeutics.com.		
	
References	
1.	 Kruiswijk,	F.,	Labuschagne,	C.	F.	&	Vousden,	K.	H.	p53	in	survival,	death	and	metabolic	
health:	a	lifeguard	with	a	licence	to	kill.	Nat	Rev	Mol	Cell	Biol	16,	393–405	(2015).	
2.	 Wade,	M.,	Li,	Y.-C.	&	Wahl,	G.	M.	MDM2,	MDMX	and	p53	in	oncogenesis	and	cancer	
therapy.	Nat	Rev	Cancer	13,	83–96	(2013).	
3.	 Khoo,	K.	H.,	Hoe,	K.	K.,	Verma,	C.	S.	&	Lane,	D.	P.	Drugging	the	p53	pathway:	
understanding	the	route	to	clinical	efficacy.	Nat	Rev	Drug	Discov	13,	217–236	(2014).	
4.	 Cummins,	J.	M.	et	al.	Tumour	suppression:	disruption	of	HAUSP	gene	stabilizes	p53.	
Nature	428,	1	p	following	486	(2004).	
5.	 Li,	M.,	Brooks,	C.	L.,	Kon,	N.	&	Gu,	W.	A	dynamic	role	of	HAUSP	in	the	p53-Mdm2	
pathway.	Mol	Cell	13,	879–886	(2004).	
6.	 Li,	M.	et	al.	Deubiquitination	of	p53	by	HAUSP	is	an	important	pathway	for	p53	
stabilization.	Nature	416,	648–653	(2002).	
7.	 Altun,	M.	et	al.	Activity-based	chemical	proteomics	accelerates	inhibitor	development	
for	deubiquitylating	enzymes.	Chem	Biol	18,	1401–1412	(2011).	
8.	 Weinstock,	J.	et	al.	Selective	Dual	Inhibitors	of	the	Cancer-Related	Deubiquitylating	
Proteases	USP7	and	USP47.	ACS	Med	Chem	Lett	3,	789–792	(2012).	
9.	 Ritorto,	M.	S.	et	al.	Screening	of	DUB	activity	and	specificity	by	MALDI-TOF	mass	
spectrometry.	Nature	Communications	5,	4763	(2014).	
10.	 Colland,	F.	et	al.	Small-molecule	inhibitor	of	USP7/HAUSP	ubiquitin	protease	stabilizes	
and	activates	p53	in	cells.	Mol.	Cancer	Ther.	8,	2286–2295	(2009).	
11.	 Reverdy,	C.	et	al.	Discovery	of	specific	inhibitors	of	human	USP7/HAUSP	
deubiquitinating	enzyme.	Chem	Biol	19,	467–477	(2012).	
12.	 Chauhan,	D.	et	al.	A	small	molecule	inhibitor	of	ubiquitin-specific	protease-7	induces	
apoptosis	in	multiple	myeloma	cells	and	overcomes	bortezomib	resistance.	Cancer	
Cell	22,	345–358	(2012).	
13.	 Wang,	L.	et	al.	Ubiquitin-specific	Protease-7	Inhibition	Impairs	Tip60-dependent	
Foxp3+	T-regulatory	Cell	Function	and	Promotes	Antitumor	Immunity.	EBioMedicine	
13,	99–112	(2016).	
14.	 Yamaguchi,	M.	et	al.	Spongiacidin	C,	a	pyrrole	alkaloid	from	the	marine	sponge	
Stylissa	massa,	functions	as	a	USP7	inhibitor.	Bioorg.	Med.	Chem.	Lett.	23,	3884–3886	
(2013).	
15.	 Dar,	A.,	Shibata,	E.	&	Dutta,	A.	Deubiquitination	of	Tip60	by	USP7	determines	the	
activity	of	the	p53-dependent	apoptotic	pathway.	Mol	Cell	Biol	33,	3309–3320	(2013).	
16.	 Fan,	Y.-H.	et	al.	USP7	inhibitor	P22077	inhibits	neuroblastoma	growth	via	inducing	
p53-mediated	apoptosis.	Cell	Death	Dis	4,	e867	(2013).	
	 11	
17.	 Lee,	G.	et	al.	Small-molecule	inhibitors	of	USP7	induce	apoptosis	through	oxidative	
and	endoplasmic	reticulum	stress	in	cancer	cells.	Biochem	Biophys	Res	Commun	470,	
181–186	(2016).	
18.	 An,	T.	et	al.	USP7	inhibitor	P5091	inhibits	Wnt	signaling	and	colorectal	tumor	growth.	
Biochem	Pharmacol	131,	29–39	(2017).	
19.	 Zhan,	M.	et	al.	Usp7	promotes	medulloblastoma	cell	survival	and	metastasis	by	
activating	Shh	pathway.	Biochem	Biophys	Res	Commun	484,	429–434	(2017).	
20.	 Hassiepen,	U.	et	al.	A	sensitive	fluorescence	intensity	assay	for	deubiquitinating	
proteases	using	ubiquitin-rhodamine110-glycine	as	substrate.	Anal.	Biochem.	371,	
201–207	(2007).	
21.	 Ioannidis,	S.	et	al.	Pyrrolo	and	pyrazolopyrimidines	as	ubiquitin-specific	protease	7	
inhibitors. US	Patent	WO2016109515	(2015).	
22.	 Borodovsky,	A.	et	al.	Chemistry-based	functional	proteomics	reveals	novel	members	
of	the	deubiquitinating	enzyme	family.	Chem	Biol	9,	1149–1159	(2002).	
23.	 McGouran,	J.	F.,	Gaertner,	S.	R.,	Altun,	M.,	Kramer,	H.	B.	&	Kessler,	B.	M.	
Deubiquitinating	enzyme	specificity	for	ubiquitin	chain	topology	profiled	by	di-
ubiquitin	activity	probes.	Chem	Biol	20,	1447–1455	(2013).	
24.	 Hu,	M.	et	al.	Crystal	structure	of	a	UBP-family	deubiquitinating	enzyme	in	isolation	
and	in	complex	with	ubiquitin	aldehyde.	Cell	111,	1041–1054	(2002).	
25.	 Ye,	Y.,	Scheel,	H.,	Hofmann,	K.	&	Komander,	D.	Dissection	of	USP	catalytic	domains	
reveals	five	common	insertion	points.	Mol	Biosyst	5,	1797–1808	(2009).	
26.	 Faesen,	A.	C.	et	al.	Mechanism	of	USP7/HAUSP	activation	by	its	C-terminal	ubiquitin-
like	domain	and	allosteric	regulation	by	GMP-synthetase.	Mol	Cell	44,	147–159	
(2011).	
27.	 Rouge,	L.	et	al.	Molecular	Understanding	of	USP7	Substrate	Recognition	and	C-
Terminal	Activation.	Structure	24,	1335–1345	(2016).	
28.	 Kim,	R.	Q.,	van	Dijk,	W.	J.	&	Sixma,	T.	K.	Structure	of	USP7	catalytic	domain	and	three	
Ubl-domains	reveals	a	connector	α-helix	with	regulatory	role.	J	Struct	Biol	195,	11–18	
(2016).	
29.	 van	der	Knaap,	J.	A.	et	al.	GMP	synthetase	stimulates	histone	H2B	deubiquitylation	by	
the	epigenetic	silencer	USP7.	Mol	Cell	17,	695–707	(2005).	
30.	 Kim,	R.	Q.	&	Sixma,	T.	K.	Regulation	of	USP7:	A	High	Incidence	of	E3	Complexes.	J	Mol	
Biol	(2017).	doi:10.1016/j.jmb.2017.05.028	
31.	 Barak,	Y.,	Juven,	T.,	Haffner,	R.	&	Oren,	M.	mdm2	expression	is	induced	by	wild	type	
p53	activity.	EMBO	J	(1993).	
32.	 Wu,	X.,	Bayle,	J.	H.,	Olson,	D.	&	Levine,	A.	J.	The	p53-mdm-2	autoregulatory	feedback	
loop.	Genes	Dev	7,	1126–1132	(1993).	
33.	 Tavana,	O.	et	al.	HAUSP	deubiquitinates	and	stabilizes	N-Myc	in	neuroblastoma.	Nat	
Med	22,	1180–1186	(2016).	
34.	 Felle,	M.	et	al.	The	USP7/Dnmt1	complex	stimulates	the	DNA	methylation	activity	of	
Dnmt1	and	regulates	the	stability	of	UHRF1.	Nucleic	Acids	Res	39,	8355–8365	(2011).	
35.	 Du,	Z.	et	al.	DNMT1	Stability	Is	Regulated	by	Proteins	Coordinating	Deubiquitination	
and	Acetylation-Driven	Ubiquitination.	Sci.	Signal.	3,	ra80–ra80	(2010).	
36.	 Clague,	M.	J.	et	al.	Deubiquitylases	from	genes	to	organism.	Physiol.	Rev.	93,	1289–
1315	(2013).	
37.	 Cohen,	P.	&	Tcherpakov,	M.	Will	the	Ubiquitin	System	Furnish	as	Many	Drug	Targets	
as	Protein	Kinases?	Cell	143,	686–693	(2010).	
	 12	
38.	 Salami,	J.	&	Crews,	C.	M.	Waste	disposal—An	attractive	strategy	for	cancer	therapy.	
Science	355,	1163–1167	(2017).	
39.	 Huang,	X.	&	Dixit,	V.	M.	Drugging	the	undruggables:	exploring	the	ubiquitin	system	
for	drug	development.	Cell	Res	26,	484–498	(2016).	
40.	 Clerici,	M.,	Luna-Vargas,	M.	P.	A.,	Faesen,	A.	C.	&	Sixma,	T.	K.	The	DUSP-Ubl	domain	of	
USP4	enhances	its	catalytic	efficiency	by	promoting	ubiquitin	exchange.	Nature	
Communications	5,	5399	(2014).	
41.	 Avvakumov,	G.	V.	et	al.	Amino-terminal	dimerization,	NRDP1-rhodanese	interaction,	
and	inhibited	catalytic	domain	conformation	of	the	ubiquitin-specific	protease	8	
(USP8).	J	Biol	Chem	281,	38061–38070	(2006).	
42.	 Li,	H.	et	al.	Allosteric	Activation	of	Ubiquitin-Specific	Proteases	by	β-Propeller	Proteins	
UAF1	and	WDR20.	Mol	Cell	63,	249–260	(2016).	
43.	 Hu,	M.	et	al.	Structure	and	mechanisms	of	the	proteasome-associated	
deubiquitinating	enzyme	USP14.	EMBO	J	24,	3747–3756	(2005).	
	 	
	 13	
Figure	1.	Properties	and	specificity	of	small	molecule	USP7	inhibitors.		
a,	Structures	of	FT671	(top)	and	FT827	(bottom)	containing	a	PyrzPPip	scaffold	(red)	and	key	
inhibitor	parameters	(see	Extended	Data	Fig.	1).	b,	Commercial	DUB	specificity	screen	(one	
replicate)	with	50	µM	FT671	and	FT827.	c-d,	Cell	lysates	(c)	or	intact	MCF7	cells	(d)	were	
incubated	with	FT671	or	FT827,	then	with	HA-UbC2Br	probes.	Modification	of	USP7	with	
ubiquitin	probe	(USP7~Ub)	was	lost	with	increasing	concentrations	of	inhibitors.	One	of	two	
independent	biological	experiments	is	shown	(see	Extended	Data	Fig.	2).	e-f,	HA-based	
immunoprecipitation	of	labelled	DUBs	from	experiments	in	c	were	subjected	to	mass	
spectrometry	(MS)-based	quantification	in	three	technical	replicates7.	Differences	in	DUB-
probe	binding	were	quantified	for	22	out	of	36	identified	DUBs	(see	Supplementary	Tables	
1,	2).	FT827	or	FT671	only	affect	USP7	(see	Methods	for	statistics).	Uncropped	images	for	
gels	are	shown	in	Supplementary	Figure	1.	
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Figure	2.	USP7-inhibitor	complex	structures.		
a,	Overall	structure	of	USP7	apo	(1NB824),	USP7-FT671,	USP7~FT827	(compounds	shown	
under	yellow	surface),	and	USP7~UbAl	(1NBF24).	See	Extended	Data	Fig.	3,	4	and	Extended	
Data	Table	2.	b-e,	Close-up	view	of	the	compound	binding	site	highlighting	key	residues.	b,	
apo	USP7;	c,	USP7~UbAl;	d,	USP7-FT671;	e,	USP7~FT827.	See	also	Extended	Data	Fig.	4.	f,	
Close-up	view	of	the	different	conformations	of	Phe409	from	b-e.	g,	Superposition	of	
reported	USP	apo	(top)	and	ubiquitin-bound	(bottom)	structures	showing	conserved	Phe	
and	Tyr	residues.		
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Figure	3.	Molecular	basis	of	selective	USP7	inhibition.	
a,	Superposition	of	USP7	apo,	USP7-FT671,	USP7~FT827	and	USP7~UbAl	structures,	showing	
that	compounds	target	the	apo	conformation.	b,	Superposition	of	USP	apo	structures	onto	
USP7-FT671.	See	also	Extended	Data	Fig.	5a.	c,	Superposition	of	USP7	apo	onto	USP7-FT671	
(left)	and	apo	USP4	(2Y6E	40,	right),	explaining	the	positions	of	key	Tyr	residues.	See	also	
Extended	Data	Fig.	5b.	d,	View	highlighting	steric	clashes	between	Tyr	residues	and	
compound	in	USP4.	e,	Compound	resistant	mutant	positions	(orange).	f,	
KM	and	kcat	determination	for	USP7	wild-type	and	mutants	(n=3	biological,	n=5	technical	
replicates).	See	Extended	Data	Fig.	6f.	Mutants	are	folded	(Extended	Data	Fig.	6e).	g,	
Compound	inhibition	for	wild-type	USP7	and	indicated	mutants.		(n=3	biological,	n=3	
technical	replicates).	
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Figure	4.	Effects	of	USP7	inhibitor	FT671	in	cell	lines.	
a,	HCT116	cells	were	treated	with	FT671	for	20	h,	and	cell	lysates	assessed	by	Western	
blotting.	One	out	of	three	biological	replicates	is	shown.	b,	U2OS	cells	were	treated	with	
0.1-10	µM	FT671	for	20	h	and	analysed	as	above.	One	out	of	two	biological	replicates	is	
shown.	c,	HCT116	cells	were	treated	with	10	µM	FT671	for	24	h	and	RNA	extracted	for	real-
time	PCR	measurements	with	primer	sets	against	indicated	transcripts	(see	Methods).	
Experiments	were	performed	in	biological	triplicate	(duplicate	for	RPS27L).	d,	Expression	of	
USP7	variants	in	HCT116	Flip-In	TRex	cells	was	induced	for	7	h	with	0.1	µg/mL	doxycycline	
followed	by	treatment	with	1	µM	FT671	or	vehicle	for	the	last	4	h.	One	out	of	two	biological	
replicates	is	shown.		Uncropped	images	for	gels	are	shown	in	Supplementary	Figure	1.	
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Figure	5.	Physiological	response	to	USP7	specific	inhibitor	FT671	
a,	MM.1S	cells	were	treated	with	increasing	amounts	of	FT671	and	viability	of	cells	was	
assessed	after	120	h	using	the	CellTiter-Glo	assay.	The	graph	displays	three	biological	
replicates,	each	point	representing	the	mean	of	three	technical	replicates.	b,	Analysis	of	p53	
levels	in	MM.1S	tumour	xenografts	after	a	single	200	mg	kg-1	dose	of	FT671	in	comparison	
to	the	vehicle	treated	xenografts	(unpaired,	two-tailed	Student’s	t-test).	Data	represents	
Mean	+/-	Standard	Deviation	(SD)	from	n=5.	See	Extended	Data	Fig.	8e	for	the	
corresponding	Western	blots.	c,	MM.1S	tumour	growth	was	significantly	reduced	in	a	dose	
dependent	manner	by	daily	treatment	with	FT671	(2-way	ANOVA).	The	data	represents	
Mean	+/-	SD	from	n=9	replicates.	See	Methods	for	statistical	analysis.	d,	Analysis	of	body	
weight	during	daily	treatment	of	MM.1S	xenograft	bearing	mice	with	100	mg	kg-1	or	200	mg	
kg-1	FT671.	Data	represent	Mean	+/-	SD	(SEM)	from	n=9	replicates.	
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Online	Methods	
	
Protein	expression	and	purification	for	USP7CD	proteins	
His-tagged	USP7CD	(residues	208-560)	and	the	corresponding	F291N	and	Q297A	point	
mutation	constructs	were	cloned	into	the	pETNHT-1	vector	and	expressed	in	E.coli	Rosetta2	
cells.	Cells	were	grown	in	TB	at	37	°C	to	an	OD600	of	0.6,	induced	with	0.5	mM	IPTG	and	
incubated	overnight	at	15	°C.	
The	cell	pellet	was	re-suspended	in	lysis	buffer	A	(50	mM	HEPES	pH7.5,	300	mM	NaCl,	1	mM	
DTT,	15	mM	Imidazole,	5	mM	benzamidine,	1	mM	AEBSF,	500	U	benzonase)	and	lysed	using	
a	Constant	Systems	Ltd	cell	disruptor.	Insoluble	material	was	removed	by	centrifugation	and	
the	supernatant	was	loaded	onto	a	HiTrap	TALON	crude	column	(GE	Healthcare)	
equilibrated	with	Ni	Buffer	A	(50	mM	HEPES	pH	7.5,	300	mM	NaCl,	1	mM	DTT,	15	mM	
imidazole)	and	washed	with	Buffer	A	+	45	mM	imidazole	until	A280	reached	baseline.	The	
protein	was	eluted	with	Ni	Buffer	B	(50mM	HEPES	pH	7.5,	300	mM	NaCl,	1	mM	DTT,	300	
mM	imidazole)	and	further	purified	using	a	HiLoad	26/60	Superdex	75	column	(GE	
Healthcare)	equilibrated	with	SEC	Buffer	(50	mM	HEPES	pH	7.5,	150	mM	NaCl,	1	mM	DTT).	
The	protein	was	concentrated	to	~20	mg	ml-1,	flash-frozen	in	liquid	N2	and	stored	at	-80	°C.	
	
Protein	expression	and	purification	for	USP7C-term	
Hi	FiveTM	Sf9	insect	cells	expressing	USP7C-term	(residues	208-1102)	were	re-suspended	in	
lysis	buffer	B	(50	mM	Tris	pH	8.0,	200	mM	NaCl,	5%	(v/v)	glycerol,	5	mM	β-
mercaptoethanol,	1	mM	PMSF)	and	lysed	using	a	Constant	Systems	Ltd	cell	disruptor.	
Insoluble	material	was	removed	by	centrifugation	and	the	supernatant	was	loaded	onto	a	
Ni-NTA	column	(GE	Healthcare)	equilibrated	with	Ni	Buffer	A	(50	mM	Tris	pH	8.0,	200	mM	
NaCl,	5%	(v/v)	glycerol,	5	mM	β-mercaptoethanol)	and	washed	with	Ni	Buffer	A	+	60	mM	
imidazole	until	A280	reached	baseline.	The	protein	was	eluted	with	Ni	Buffer	B	(50	mM	Tris	
pH	8.0,	200	mM	NaCl,	5%	glycerol,	5	mM	β-mercaptoethanol,	250	mM	imidazole).	The	
protein	was	further	purified	using	a	HiLoad	16/600	Superdex	200	column	(GE	Healthcare)	
equilibrated	with	50	mM	Tris	pH	8.0,	200	mM	NaCl,	5%	(v/v)	glycerol,	5	mM	DTT.	The	
protein	was	concentrated	to	~10	mg	ml-1,	flash-frozen	in	liquid	N2	and	stored	at	-80	°C.	
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Chemical	synthesis	of	USP7	compounds	
FT671	and	FT827	were	prepared	in	agreement	with	the	procedures	described	in	detail	in	21.	
The	chemical	synthesis	is	described	in	Supplementary	Information,	and	the	characterisation	
data	can	be	found	in	Supplementary	Chemistry	Data.		
	
Surface	plasmon	resonance	(SPR)	
Studies	of	binding	kinetics	were	performed	on	a	Biacore	T200	(GE	Healthcare).	His-tagged	
USP7CD	WT	and	mutant	proteins,	and	His-tagged	PH	domain	of	Akt	(non-DUB	negative	
control)	were	immobilised	in	10	mM	HEPES	pH	7.5,	150	mM	NaCl,	2	mM	CaCl2,	1	mM	β-
mercaptoethanol,	5%	(v/v)	glycerol,	0.01%	Triton-X	100	on	a	Biacore	Series	S	NTA	chip	
through	N-terminal	His	tag	capture,	followed	by	amine-coupling	with	
EDC/NHS/Ethanolamine	as	per	manufacturer’s	instructions,	aiming	for	an	immobilisation	
level	of	10,000	RU.	
Compounds	were	tested	in	duplicate	in	two-fold	dilution	series	in	immobilisation	buffer	
supplemented	with	3%	(v/v)	DMSO,	with	a	flow	rate	of	30	µl	min-1,	a	contact	time	of	60	s,	
and	a	dissociation	time	of	300	s.	A	solvent	correction	curve	from	2.4-3.8	%	(v/v)	DMSO	was	
included.	Ubiquitin	at	20	μM	was	injected	between	compounds	as	a	positive	control,	and	
ten-point	dilution	curves	of	ubiquitin	from	500	µM	were	included	before	and	after	the	
compounds	to	ensure	surface	integrity	was	retained	throughout.	
Analysis	was	performed	using	the	Biacore	Evaluation	software	version	3.0	using	a	kinetic	fit	
and	a	1:1	binding	model	with	the	Rmax	fit	locally.	Representative	curves	were	exported	and	
re-plotted	in	GraphPad	Prism.	
The	fact	that	the	irreversible	compound	FT827	displays	reversible	behaviour	is	consistent	
with	its	measured	kinact	value	(0.0003	s-1	corresponding	to	t½	=	38.5	min)	and	the	short	
association	time	(60	s	=	0.026	x	t½),	from	which	the	percentage	of	complexes	forming	a	
covalent	bond	would	be	predicted	to	be	100	–	(100/20.026)	=	1.8	%.		
	
Circular	Dichroism	(CD)	
Analysis	was	carried	out	at	the	University	of	Cambridge’s	Biophysics	Facility,	using	an	Aviv	
Model	410	Circular	Dichroism	Spectrometer.	USP7CD	WT,	USP7CD	F291N,	USP7CD	Q297A,	and	
USP7CD	Y465N	were	buffer	exchanged	into	CD	buffer	(10	mM	potassium	phosphate	pH	7.5,	
100	mM	potassium	fluoride,	1	mM	DTT)	using	a	Zeba	Spin	column,	before	dilution	to	~0.2	
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mg	ml-1.	CD	experiments	were	carried	out	at	room	temperature,	reading	at	wavelengths	
from	250	nm	to	189	nm	in	1	nm	steps,	with	an	averaging	time	of	3	s,	setting	time	of	0.33	s,	
and	3	scans	per	wavelength.	Data	from	scans	were	averaged,	buffer-subtracted	and	
smoothed,	and	data	exported	to	GraphPad	Prism	for	analysis.	
	
In	vitro	USP7	activity	assay	
Fluorescence	intensity	measurements	were	used	to	monitor	the	cleavage	of	a	
monoubiquitinated	ubiquitin-rhodamine	substrate20.	All	activity	assays	were	performed	in	
black	384	well	ProxiPlates	(PerkinElmer)	in	20	mM	Tris	pH	8.0,	2	mM	CaCl2,	1	mM	reduced	
glutathione,	0.01%	(v/v)	Triton	X100,	0.01%	(v/v)	Prionex	and	an	assay	volume	of	10	µL.	
	
To	determine	compound	IC50s,	compounds	were	diluted	in	100%	DMSO	in	three-fold	12-	
point	dilution	series	from	100	µM.	100	nL	of	100-fold	concentrated	solutions	were	
dispensed	into	black	384-well	Proxiplates	(Perkin	Elmer)	using	an	Echo	(Labcyte).	25	nM	
Ubiquitin-Rhodamine	110	(Boston	Biochem),	along	with	recombinant	USP7CD	(3	nM),	or	
USP7C-term	(30-125	pM,	depending	on	batch	activity)	were	added	and	the	plates	incubated	at	
room	temperature	for	1	h.	The	reaction	was	terminated	by	adding	2.5	µL	citric	acid	to	a	final	
concentration	of	10	mM	prior	to	measuring	fluorescence	intensity	on	a	Pherastar	(BMG	
Labtech)	with	a	485	nm	excitation/520	nm	emission	optic	module.		
		
To	determine	KM/kcat	values,	recombinant	USP7CD	(3	nM),	USP7CD	F291N	(0.2	nM),	USP7CD	
Q297A	(16	nM),	or	USP7CD	Y465N	(100	nM),	were	incubated	at	room	temperature	for	1	h	
with	a	two-fold	15-point	dilution	series	of	Ubiquitin-Rhodamine	110	(Boston	Biochem)	from	
a	top	concentration	of	5	µM.	Upon	addition	of	the	substrate,	fluorescence	intensity	was	
monitored	kinetically	on	a	Pherastar	(BMG	Labtech)	with	a	485	nm	excitation/520	nm	
emission	optic	module.	RFU	were	converted	to	pmol	ubiquitin-rhodamine	converted.	Pmol	
protein-1	by	assuming	100%	substrate	conversion	at	each	ubiquitin-rhodamine	
concentration	in	the	presence	of	excess	enzyme.	Converted	data	were	plotted	in	Graphpad	
Prism	and	the	initial	rate	was	determined	from	the	slop	of	a	linear	fit	of	the	early	part	of	the	
curve	(over	~10	min).	Initial	rates	were	plotted	against	substrate	conversion	and	fitted	to	a	
kcat	fit	in	Graphpad	Prism.	
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kinact/KI	determination	
For	the	covalent	compound	FT827,	a	kinact/KI	assay	was	carried	out	using	125	pM	USP7C-term	
as	described	above.	Upon	addition	of	the	substrate,	fluorescence	intensity	was	monitored	
kinetically	over	3	h.	Analysis	was	performed	in	ActivityBase	(ID	Business	Solutions	Limited).	
Kinetic	progress	curves	were	fitted	to	equation	y	=	ymax(1-exp(-kobs.x))	to	determine	kobs.	kobs	
was	then	plotted	against	the	inhibitor	concentration	and	fitted	to	the	equation	y	=	
kinact/(1+(KI/x))	to	determine	kinact	and	KI.	
	
In	vitro	compound	specificity	panel		
DUBprofiler™	assays	were	performed	by	Ubiquigent	Ltd.	(Dundee,	UK).	FT671	was	tested	at	
50	µM	using	100	nM	Ubiquitin-rhodamine	110	as	the	substrate.	For	most	enzymes,	KM	
exceeds	substrate	concentration.		For	USP11,	USP15,	USP20,	UCHL1,	UCHL3	and	OTUD3,	the	
KM	was	similar	or	lower	than	substrate	concentration,	and	the	potency	of	competitive	
inhibitors	may	be	underestimated.	
Linearity	of	enzyme	activity	through	the	assay	incubation	time	was	validated	for	each	DUB	
enzyme	by	Ubiquigent	Ltd.	All	assays	were	operating	at	<40%	substrate	conversion	and	data	
are	reported	as	a	percentage	of	the	activity	of	the	enzyme	in	the	presence	of	the	test	
compound	relative	to	‘plus’	(100%	activity)	and	‘minus’	(0%	activity)	DUB	enzyme	controls.		
Four	‘plus’	enzyme	control	wells	and	‘Product	Modulator’	control	wells	were	run	on	each	
DUBprofiler™	assay	plate.	Eight	‘minus’	enzyme	control	wells	were	run	on	each	
DUBprofiler™	assay	plate.		
	
DUB	profiling	assays	using	ubiquitin-based	active	site	directed	probes	
Molecular	probes	based	on	the	ubiquitin	scaffold	were	generated	and	used	essentially	as	
described7,23		with	some	modifications.	In	brief,	HA-tagged	ubiquitin	bromoethyl	(HA-
UbC2Br)	was	synthesised	by	expressing	the	fusion	protein	HA-Ub75-Intein-chitin	binding	
domain	in	E.	coli	BL21	strains22.	Bacterial	lysates	were	prepared,	and	the	fusion	protein	
purified	over	a	chitin	binding	column	(NEB	labs,	UK).	HA-Ub75-thioester	was	obtained	by	
incubating	column	material	with	mercaptosulfonate	sodium	salt	(MESNa)	overnight	at	37	oC.	
HA-Ub75-thioester	material	was	desalted	against	PBS	using	a	PD10	column	according	to	the	
manufacturer’s	instructions	(GE	Healthcare).	500	µl	of	1-2	mg	ml-1	of	HA-Ub75-thiolester	was	
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incubated	with	0.2	mmol	of	bromo-ethylamine	at	pH	8-9	(adjusted	by	adding	NaOH)	for	20	
min	at	room	temperature,	followed	by	a	desalting	step	against	phosphate	buffer	(pH	8)	as	
described	above.	Ubiquitin	probe	material	was	concentrated	using	3,000	MW	filters	
(Sartorius)	until	a	concentration	of	~1	mg	ml-1,	and	kept	as	aliquots	at	-80°C	until	use.	
	
DUB	competition	assays	with	cell	extracts	and	with	cells	(in	situ)	
Human	breast	cancer	MCF7	cells	were	cultured	in	DMEM	medium	supplemented	with	10%	
FCS,	1%	penicillin/streptomycin	and	1%	glutamine	at	37	oC	and	5%	CO2.	Crude	extracts	were	
prepared	as	described	previously	using	glass-bead	lysis	in	50	mM	Tris	pH	7.4,	5	mM	
MgCl2·6H2O,	0.5	mM	EDTA,	250	mM	sucrose	and	1	mM	DTT7,23	.	For	experiments	with	crude	
cell	extracts,	50 µg	of	MCF7	cell	lysate	was	incubated	with	different	concentrations	of	either	
FT671	or	FT827	for	1	h	at	37	oC,	followed	by	addition	of	1 µg	HA-UbC2Br	and	incubation	for	
5	min	at	37	oC.	Incubation	with	Ub-probe	was	optimised	to	minimise	replacement	of	non-
covalent	inhibitor	FT671	by	the	covalent	probe.	Samples	were	subsequently	boiled	in	
reducing	SDS-sample	buffer,	separated	by	SDS-PAGE	and	analysed	by	Western	blotting	using	
anti-HA	(12CA5,	Roche,	#11583816001,	1:2000)	or	anti-USP7	(Enzo	#PW0540,	1:1000)	or	
anti-β-Actin	(Abcam	#ab8227,	1:2000)	antibodies.	5x106	intact	MCF7	cells	were	incubated	
with	different	concentrations	of	inhibitors	in	cultured	medium	for	4	h	at	37	oC,	followed	by	
glass-bead	lysis,	labelling	with	HA-UbC2Br	probe	and	analysis	by	SDS-PAGE	and	Western	
blotting	as	described	above.		
	
Mass	spectrometry	based	DUB	inhibitor	profiling	assays	
Ub-probe	pulldown	experiments	in	presence	of	different	concentrations	of	the	inhibitors	
FT671	and	FT827	were	performed	essentially	as	described7,23	with	some	modifications.	In	
brief,	immunoprecipitated	material	was	subjected	to	in-solution	trypsin	digestion	44	and	
desalted	using	C18	SepPak	cartridges	(Waters)	according	to	the	manufacturer’s	instructions.	
Digested	samples	were	analysed	in	triplicate	by	nano-UPLC-MS/MS	using	a	Dionex	Ultimate	
3000	nano	UPLC	with	EASY	spray	column	(75	μm	x	500	mm,	2	μm	particle	size,	Thermo	
Scientific)	with	a	60	min	gradient	of	0.1	%	(v/v)	formic	acid	in	5%	(v/v)	DMSO	to	0.1%	(v/v)	
formic	acid	to	35%	(v/v)	acetonitrile	in	5%	(v/v)	DMSO	at	a	flow	rate	of	~250	nl/min	(~600	
bar/40	oC	column	temperature).	MS	data	were	acquired	with	an	Orbitrap	Q	Exactive	High	
Field	(HF)	instrument	in	which	survey	scans	were	acquired	at	a	resolution	of	60.000	@	400	
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m/z	and	the	20	most	abundant	precursors	were	selected	for	CID	fragmentation.	From	raw	
MS	files,	peak	list	files	were	generated	with	MSConvert	(Proteowizard	V3.0.5211)	using	the	
200	most	abundant	peaks/spectra.	The	Mascot	(V2.3,	Matrix	Science)	search	engine	was	
used	for	protein	identification	at	a	false	discovery	rate	of	1	%,	mass	deviation	of	10	ppm	for	
MS1	and	0.06	Da	(Q	Exactive	HF)	for	MS2	spectra,	Cys	carbamidylation	as	fixed	modification,	
Met	oxidation	and	Gln	deamidation	as	variable	modification.	Searches	were	performed	
against	the	UniProtKB	human	sequence	data	base	(retrieved	15.10.2014).	Label-free	
quantitation	was	performed	using	MaxQuant	Software	(v1.5.2),	and	data	were	further	
analysed	using	GraphPad	Prism	software	(v7.0)	and	Microsoft	Excel.	For	the	statistical	
analysis	in	Fig.	1e	and	1f,	we	applied	two-way	ANOVA	tests	including	multiple	comparison	
testing	via	the	Dunnett	method	available	through	the	GraphPad	Prism	software.	P	value	
style	is	GP:	0.1234	(ns),	0.0332	(*),	0.0021	(**),	0.0002	(***),	<0.0001	(****)	
	
Expression	and	purification	of	USP7CD	for	crystallography	
GST-tagged	USP7CD	(residues	208-560)	was	cloned	into	the	pGEX4T	vector	and	expressed	in	
E.	coli	Rosetta2	cells	as	described	in24.	Cells	were	grown	in	TB	at	37	°C	to	an	OD600	of	0.6,	
induced	with	0.4	mM	IPTG	and	incubated	overnight	at	18	°C.			
The	cell	pellet	was	re-suspended	in	lysis	buffer	C	(50	mM	HEPES	pH	7.5,	300	mM	NaCl,	1	
mM	DTT,	5	mM	benzamidine,	1	mM	PMSF)	and	lysed	using	a	Constant	Systems	Ltd	cell	
disruptor.	Insoluble	material	was	removed	by	centrifugation	and	the	supernatant	was	
loaded	onto	a	column	packed	with	Glutathione	Sepharose	4B	beads	(GE	Healthcare)	and	
washed	with	GST	Buffer	(50	mM	HEPES	pH	7.5,	150	mM	NaCl,	1	mM	DTT)	until	A280	reached	
baseline.	
The	GST	tag	was	cleaved	off-column	using	thrombin	and	removed	by	reapplying	the	sample	
onto	the	GSH	column.	USP7CD	was	then	separated	from	thrombin	using	Benzamidine	
Sepharose	beads	(GE	Healthcare),	and	purified	further	by	gel	filtration	(Superdex	200,	GE	
Healthcare	in	50	mM	HEPES	pH	7.5,	150	mM	NaCl,	1	mM	DTT).	Protein	was	concentrated	to	
17.5	mg	ml-1,	aliquoted,	flash-frozen	in	liquid	N2	and	stored	at	-80	°C. 
	
Crystallisation	
USP7CD-FT671	structure	
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USP7CD	was	crystallised	from	25	%	(w/v)	polyethylene	glycol	(PEG)	1500,	100	mM	MMT	(DL-
malic	acid,	MES	monohydrate,	Tris,	pH	8.0)	at	20	°C	for	24	h	in	sitting-drop	vapour	diffusion	
experiments.	A	crystal	was	soaked	in	a	solution	containing	1.25	mM	FT671,	30	%	(v/v)	PEG	
400,	17.5	%	(w/v)	PEG	1500,	70	mM	MMT	pH	8.0	for	72	h	and	flash-cooled	in	liquid	N2.		
USP7CD-FT827	structure	
USP7CD	was	crystallised	from	20	%	(w/v)	PEG	3350,	100	mM	Bis-Tris	propane	pH	7.5,	0.2	M	
sodium	formate	at	20	°C	for	24	h	in	sitting-drop	vapour	diffusion	experiments.	A	crystal	was	
soaked	in	a	solution	containing	2	mM	FT827,	30	%	(v/v)	PEG	400,	14	%	(w/v)	PEG	3350,	70	
mM	Bis-Tris	propane	pH	7.5,	140	mM	sodium	formate	for	24	h	and	was	flash-cooled	in	liquid	
N2.	
	
Data	collection	and	refinement		
Data	for	the	USP7-FT671	and	FT827	complex	structures	were	collected	at	Diamond	Light	
Source	(Harwell,	UK),	beamline	I03	and	I04,	respectively,	at	100	K,	and	processed	to	2.35	Å	
and	2.33	Å	resolution,	respectively,	using	Xia245.	Structures	were	solved	by	molecular	
replacement	with	PHASER46	and	human	USP7CD	(PDB	1NB824)	as	the	search	model.	The	
model	was	rebuilt	using	COOT47	and	refined	using	REFMAC548.	Data	collection	and	
refinement	statistics	are	shown	in	Extended	Data	Table	2.	Ramachandran	statistics	are	as	
follows:	USP7-FT671:	95.3%	favoured	/	4.2%	allowed	/	0.5%	outliers	and	USP7~FT827:	
94.8%	favoured	/	4.7	%	allowed	/	0.5	%	outliers.	Figures	were	generated	with	PyMol	
(www.pymol.org),	and	Molecular	Operating	Environment	(MOE)	(v.	2013.08,	Montreal,	
Canada).		
		
Cellular	studies	with	USP7	inhibitors	
MM.1S	cells	were	acquired	from	ATCC	(Manassas,	VA,	CRL-2974)	and	their	identity	was	
authenticated	using	STR	analysis.	HCT116	cells	were	acquired	from	ATCC	(ATCC-CCL-247,	
October	2016).	IMR-32	were	acquired	from	Sigma	(cat.	number	86041809,	January	
2016).	MCF7	were	acquired	from	ATCC	(HTB-22).	U2OS	were	acquired	from	ATCC	(HTB-96,	
authenticated	in	March	2017).	HCT116,	MCF7	and	U2OS	cells	were	authenticated	
frequently.	Cell	lines	used	in	this	study	were	verified	to	be	mycoplasma	negative	before	
undertaking	any	experiments	with	them.	
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Knockdown	studies	and	Western	blotting	
MM.1S	cells	(ATCC)	were	grown,	in	log	phase,	in	RPMI-1640	supplemented	with	10	%	fetal	
bovine	serum	and	antibiotic/antimycotic	solution.		FT671	was	added	to	cells	at	a	final	
concentration	of	10	μM	for	0	h,	2	h,	4h,	8	h	or	24	h,	as	indicated.		Cells	were	harvested	from	
both	the	liquid	fraction	and	the	adherent	fraction	by	collecting,	washing	with	chilled	PBS	
and	snap-freezing	at	-80°C.	
Cell	lysate	was	prepared	for	western	blotting	by	lysing	with	RIPA	lysis	buffer	(Boston	
Bioproducts),	followed	by	separation	by	SDS-PAGE	and	transfer	to	PVDF	membrane	using	
the	iBlot2	system	(Life	Technologies).		Blots	were	probed	with	antibodies	against	MDM2	
(TA590124,	Origene),	p53	(DO-1,	Santa	Cruz	Biotechnology),	p21	(12D1,	Cell	Signaling	
Technologies)	and	β-actin	(13E5,	Cell	Signaling	Technologies).		Membranes	were	developed	
using	Pierce	ECL	Western	blotting	substrate	(Fisher)	and	imaged	on	the	Amersham	
Bioluminescent	Imager	(GE	Healthcare).	
HCT116,	U2OS	and	IMR-32	cells	were	cultured	in	DMEM	medium	with	Glutamax	
supplemented	with	10	%	FBS,	1	%	nonessential	amino	acids,	and	1	%	penicillin/streptomycin	
(Gibco).	For	cellular	assays	with	compound,	cells	were	treated	with	0.1	µM,	1	µM,	3	µM	and	
10	µM	FT671	or	vehicle	as	indicated.	For	siRNA	experiments,	cells	were	transfected	with	
non-targeting	(NT1)	or	target	specific	siRNA	oligos	(Dharmacon	On	Target	Plus	oligos,	
Thermo	Fisher	Scientific,	Supplementary	Table	3)	at	40	nM	final	concentration	for	72	h	
using	RNAiMAX	(Invitrogen).	Cells	were	lysed	with	RIPA	buffer	(10	mM	Tris-HCl	pH	7.5,	150	
mM	NaCl,	1	%	(v/v)	NP40,	0.1	%	(v/v)	SDS,	1	%	(v/v)	sodium	deoxycholate)	supplemented	
with	mammalian	protease	inhibitor	(Sigma)	and	phosphatase	inhibitor	cocktails	(Roche).	20	
µg	of	protein	lysates	were	resolved	by	SDS-PAGE	(Invitrogen	4-12	%	NuPage	or	10	%	Biorad	
gels)	and	transferred	to	nitrocellulose	(Amersham	Protran,	GE	Healthcare).	Membranes	
were	probed	with	anti-p53	(DO1,	Santa	Cruz),	anti-MDM2	(IF2,	Calbiochem),	anti-MDM2	
(2A10	and	4B2,	gifts	from	Ted	Hupp,	University	of	Edinburgh),	anti-p21	(F-5,	Santa	Cruz),	
anti-USP7	(Abcam),	anti-N-Myc	(Cell	Signaling),	anti-DNMT1	(D63A6,	XP®	Rabbit	mAb	Cell	
Signaling	#5032),	anti-UHRF1	(H-8,	Santa	Cruz	Biotechnology	sc-373750),	and	anti-β-actin	
(Abcam).	Visualisation	and	quantitation	of	western	blots	were	carried	out	using	an	Odyssey	
infrared	scanner	(LI-COR	Biosciences,	Lincoln,	NE).	
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Compound	resistant	cell	lines	
GFP-USP7	 was	 subcloned	 from	 pEGFP-C-GW-USP7	 into	 pCDNA5-FRT-TO	 (Invitrogen).	 The	
coding	 sequences	 for	 F291N	 and	 Q297A	 were	 subcloned	 from	 pETNHT_USP7	 K208-E560	
(F291N)	and	pETNHT_USP7	K208-E560	(Q297A)	plasmids	into	pCDNA5-GFP-USP7.		
HCT116	Flp-In	TRex	cells	(gift	from	Stephen	Taylor,	University	of	Manchester)	were	cultured	
in	 DMEM	 with	 Glutamax	 supplemented	 with	 10	 %	 FBS,	 1	 %	 nonessential	 amino	 acids	
solution,	1	%	penicillin/streptomycin,	10	µg/mL	zeocin,	and	4	µg/mL	blasticidin	(Invitrogen).	
HCT116	 Flip-In	 Trex	 cells	 were	 transfected	 with	 Lipofectamine	 LTX,	 with	 Plus	 Reagent	
(Invitrogen),	 with	 pOG44	 and	 either	 pEF5-GFP,	 pCDNA5-GFP-USP7WT,	 pCDNA5-GFP-
USP7F291N	 or	 pCDNA5-GFP-USP7Q297A.	 Two	 days	 after	 transfection,	 Hygromycin	 B	 (50	
µg/mL,	Invitrogen)	was	added	and	cells	were	kept	under	selection	for	3	weeks.		
Stably	 transfected	 HCT116	 Flip-In	 Trex	 GFP,	 GFP-USP7WT,	 GFP-USP7F291N	 and	 GFP-
USP7Q297A	cells	were	incubated	with	0.1	µg/mL	Doxycycline	for	3	h,	and	then	treated	with	
1	µM	and	3	µM	of	FT671	or	vehicle	for	4	h	in	presence	of	doxycycline.	Cells	were	lysed	with	
RIPA	 lysis	 buffer	 supplemented	 with	 mammalian	 protease	 inhibitor	 (Sigma)	 and	
phosphatase	 inhibitor	cocktails	 (Roche).	Protein	 lysates	were	 resolved	by	SDS-PAGE	 (10	%	
gel,	BioRad),	transferred	to	nitrocellulose	(Amersham	Protran,	GE	Healthcare).	Membranes	
were	probed	as	indicated.	
	
Quantitative	PCR	analysis	
MM.1S	or	HCT116	cells	(ATCC)	were	grown,	in	log	phase,	in	RPMI-1640	supplemented	with	
10%	fetal	bovine	serum	and	an	antibiotic/antimycotic	solution.	FT671	was	added	to	cells	at	
a	final	concentration	of	10	μM	for	0,	2,	4	8	or	24	h,	as	indicated.		Cells	were	harvested	from	
both	the	liquid	fraction	and	the	adherent	fraction	by	collecting,	washing	with	chilled	PBS	
and	snap-freezing	at	-80°C.	
RNA	was	harvested	from	cells	using	the	RNeasy	Kit	(Qiagen)	and	quantitated	by	Nanodrop.		
Transcripts	were	amplified	and	quantitated	using	the	TaqMan	RNA-to-Ct	1-step	kit	(Life	
Technologies)	with	TaqMan	Probe	sets	on	the	QuantStudio7	Flex	(Life	Technologies)	
according	to	the	manufacturer’s	directions.	TaqMan	primer	sets	were	used	for	the	following	
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genes,	CDKN1A	(Hs00355782_m1,	Life	Technologies),	BBC3	(Hs00248075_m1),	MDM2	
(H200540450_s1),	RPS27L	(Hs00955038_g1),	Myc	(Hs00153408_m1),	MCL1	
(Hs01050896_m1),	GAPDH	(Hs0392907g1).	Cycle	number	and	fold-change	were	quantified	
using	the	software	for	the	QuantStudio7	Flex	and	plotted	in	Prism	7.0. 
	
Meso	Scale	Discovery	MDM2	ubiquitination	assay	
MM.1S	cells	were	plated	in	a	96-well	format	(26.7K	cells	/	well)	and	treated	at	the	same	
time	with	compound	FT671	(final	concentration	10	µM,	0.1%	DMSO)	and	proteasome	
inhibitor	MG132	(final	concentration	25	µM)	(AlfaAesar,	cat	#:	J63250LB0)	or	0.1%	DMSO,	
and	harvested	at	indicated	time	points.	The	commercially	available	Meso	Scale	Discovery	
assay	kit	for	Ubiquitinated	and	Total	MDM2	in	whole	cell	lysate	(MSD,	cat	#:	K15168D)	was	
used	as	according	to	the	manufacturer	instruction	to	lyse	and	process	the	cell	pellets.	
Measured	is	the	ratio	of	ubiquitinated	versus	non-ubiquitinated	total	MDM2.	Raw	data	from	
a	triplicate	experiment	was	plotted	with	Graphpad	Prism.		
	
Cell	viability	studies	
MM.1S	 were	 plated	 at	 starting	 density	 3500	 cells/well	 in	 40	 µl	 of	 RPMI-1640	 (Corning)	
supplemented	 with	 2	 mM	 L-glutamine,	 10	 %	 fetal	 bovine	 serum	 (Corning),	 1	 %	
penicillin/streptomycin,	 and	 10	 mM	 HEPES,	 pH	 7.4.	 Cells	 were	 plated	 in	 384-well	 black	
plates	 (Corning	3712)	and	 incubated	at	37	°C,	5	%	CO2	 in	humidified	atmosphere	 for	12	h	
before	DMSO-solubilised	FT671	was	added	using	an	ECHO	525	acoustic	dispenser.	The	final	
DMSO	 concentration	was	 0.5	%	 (v/v).	 After	 compound	 addition,	 cells	were	 incubated	 for	
120	 h	 at	 37	 °C,	 5	 %	 CO2	 in	 humidified	 atmosphere.	 Experiments	 were	 performed	 in	
triplicate,	at	the	same	time	on	different	plates.	
The	viability	assay	was	performed	using	CellTiter-Glo	2.0	(Promega)	following	manufacturer	
instructions.	Luminescence	was	measured	using	an	Envision	plate	reader	(PerkinElmer)	and	
normalised	to	the	samples	treated	with	0.5	%	(v/v)	DMSO.	The	IC50	values	were	calculated	
using	nonlinear	regression	algorithms	in	ActivityBase	(ID	Business	Solutions	Limited).	
	
MM.1S	xenograft	studies		
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6	to	8-week-old	female	NOD	SCID	mice	(Vital	River	Laboratory	Animal	Technology	Co,	
Beijing,	China)	were	irradiated	(200	rads)	with	a	Co60	irradiator	source	24	h	prior	to	
subcutaneous	inoculation	of	5x106	MM.1S	tumour	cells	in	1:1	mixture	of	RPMI-1640	and	
Matrigel.	The	efficacy	study	was	initiated	when	tumours	had	reached	an	average	volume	of	
159	mm3.	Mice	received	a	lead-in	dose	of	25	mg	kg-1	of	FT671	24h	prior	to	starting	on	the	
dosing	regimen	of	100	or	200	mg	kg-1	FT671	(QD,	p.o.	by	oral	gavage).		10%	DMA/90%	
PEG400	served	as	a	vehicle	control	(n=9	mice/group).	For	the	statistical	analysis	of	
differences	in	tumour	volumes	between	treatment	groups,	a	2-way	ANOVA	with	repeated	
measures	was	performed	followed	by	correction	for	multiple	comparisons	using	statistical	
hypothesis	testing	(Tukey).		
For	the	PK/PD	study,	a	single	administration	of	200,	75	or	25	mg	kg-1	FT671	was	given	p.o.	by	
oral	gavage	when	tumours	had	reached	an	average	volume	of	318	mm3.	10	%	DMA	/	90	%	
PEG	400	served	as	a	vehicle	control	(n=5	mice/group/time	point).	Tumour	samples	were	
harvested	at	0.5	h,	2	h,	6	h	and	24	h	time	points	and	flash	frozen	for	subsequent	analysis.	
Vehicle	control	samples	were	harvested	at	24	h	time	point.	
For	xenograft	tumour	tissue	-analysis,	flash	frozen	tissue	samples	were	lysed	in	Tris	Lysis	
buffer	(Meso	Scale	Discovery,	Rockville,	MD)	complemented	with	protease	and	phosphatase	
inhibitors	(Roche,	Mannheim,	Germany).	p53	levels	were	analysed	from	20	µg	of	
protein/sample	by	western	blotting	with	anti-p53-antibodies	(Santa	Cruz	sc-126,	1:200),	
anti-p21	(Cell	Signaling	Technology	#4970,	1:1000).	β-Actin	(Cell	Signaling	Technology	
#2946,	1:1000)	was	used	to	normalise	p53-levels.	Secondary	antibodies	were	HRP-
conjugated	anti-rabbit	(Cell	Signaling	Technology	#7074,	1:1000)	and	anti-mouse	(Cell	
Signaling	Technology	#7076,	1:1000).	ECL	chemiluminescence	detection	reagents	were	used	
for	detection	and	target	bands	were	analysed	using	FluoChem	FC2	software.	
	
Animal	experiments		
All	 animal	 experiments	 were	 performed	 at	 Pharmaron	 (Beijing,	 China).	 	 All	 the	 animal	
experiments	 were	 performed	 according	 to	 the	 guidelines	 approved	 by	 the	 Institutional	
Animal	 Care	 and	 Use	 Committee	 (IACUC)	 of	 Pharmaron	 (Beijing,	 China)	 following	 the	
guidance	 of	 the	 Association	 for	 Assessment	 and	 Accreditation	 of	 Laboratory	 Animal	 Care	
(AAALAC).	The	protocol	defines	3000	mm3	as	the	maximum	tumour	volume	for	a	humane	
endpoint	and	animals	with	larger	tumours	were	euthanised.		
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Data	availability	
FT671	and	FT827	are	available	from	FORMA	Therapeutics.	All	reagents	are	available	by	
reasonable	requests	to	the	corresponding	authors.	Crystallographic	coordinates	and	
structure	factors	have	been	deposited	with	the	Protein	Data	Bank	under	accession	codes	
5NGE	(USP7-FT671)	and	5NGF	(USP7~FT827).	MS	data	are	available	via	ProteomeXchange	
with	identifier	PXD006418	and	can	also	be	found	in	Supplementary	Tables	1	and	2.	
Uncropped	images	of	all	gels	and	blots	in	this	study	can	be	found	in	Supplementary	Figure	
1.	Chemical	characterisation	of	FT671	and	FT827	can	be	found	in	Supplementary	
Information	(&	Supplementary	Chemistry	Data).	Source	data	are	provided	for	animal	
experiments	(Fig.	5b-d,	Extended	Data	Fig.	8e)	as	well	as	for	biophysical	compound	
characterization	and	biological	experiments.	
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Extended	Data	Figure	1.	Compound	characterisation.			
a,	Schematic	diagram	of	the	USP7	constructs	used	in	this	study.	b,	Representative	SPR	
sensorgrams	of	USP7CD	and	Akt	Pleckstrin	homology	(PH)	domain	(negative	control)	to	
measure	affinity	parameters	(Kd)	of	FT671	and	FT827.	Compounds	were	tested	in	2-fold	
dilutions	from	50	µM	(FT827)	or	1.56	µM	(FT671).	Sensorgrams	are	plotted	showing	two	
technical	replicates.	These	data	are	representative	of	three	biological	replicates.	Errors	
represent	standard	deviation	of	the	mean.	c,	IC50	curves	for	FT671	against	USP7C-term	(Δ)	and	
USP7CD	(n)	in	the	ubiquitin-rhodamine	assay.	The	graph	displays	three	biological	replicates,	
each	point	representing	the	average	of	three	technical	replicates.	d,	Time	course	of	the	
inhibition	of	USP7C-term	by	the	covalent	inhibitor	FT827	used	to	derive	kobs	values	at	each	
concentration.	kobs	plot	for	covalent	inhibitor	FT827	used	to	derive	the	kinetic	parameters.	
18	biological	replicates	were	run	in	singlicate,	a	representative	singlicate	is	shown.	See	
Supplementary	Information	for	a	detailed	description	of	the	synthesis	and	Supplementary	
Chemistry	Data	for	the	characterisation	of	the	inhibitor	compounds.		
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Extended	Data	Figure	2.	USP7	target	engagement	and	specificity	in	MCF7	cells.		
a,	Schematic	representation	of	DUB	activity-based	profiling	of	small	molecule	inhibitors.	
Compounds	were	incubated	either	with	intact	MCF7	cells	(in	situ)	or	crude	cell	extracts,	
followed	by	labelling	with	the	active	site	DUB	probe	HA-UbC2Br.	DUBs	either	targeted	by	
compounds	or	labelled	by	the	DUB	probe	were	visualised	either	by	Western	blotting	or	
subjected	to	immunoprecipitation	for	enrichment	and	analysis	by	quantitative	mass	
spectrometry	7,23.	b-e,	FT671	and	FT827	selectively	target	USP7	and	disallow	HA-UbC2Br	
binding,	but	do	not	notably	interact	with	other	DUBs	as	assessed	by	anti-HA	
immunoblotting.	One	out	of	two	independent	biological	replicates	is	shown.	b,	MCF7	cell	
extracts	incubated	with	FT617,	c,	intact	MCF7	cells	incubated	with	FT671,	d,	MCF7	cell	
extracts	incubated	with	FT827,	e,	intact	MCF7	cells	incubated	with	FT827.	f,	
Immunoprecipitation	of	cellular	DUBs	captured	by	HA-UbC2Br	labelling	for	10	min	after	
incubation	of	MCF7	cell	extracts	with	DMSO,	1	µM	or	10	µM	of	FT671,	FT827	or	50	µM	
P22077	for	60	min.	Immunoprecipitated	material	was	separated	by	SDS-PAGE	and	analysed	
by	Western	blotting	using	the	indicated	antibodies.	g,	FT671,	FT827	and	P22077	were	
incubated	with	MCF7	cell	extracts	at	the	indicated	concentrations	for	60	min,	followed	by	
labelling	with	HA-UbC2Br	for	either	5	min	(left)	or	60	min	(right).	Immunoprecipitated	
material	was	separated	by	SDS-PAGE	and	analysed	by	Western	blotting	using	the	indicated	
antibodies.	Uncropped	images	for	gels	are	shown	in	Supplementary	Figure	1.	
.	
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Extended	Data	Figure	3.	Electron	density	for	FT827	and	FT671.	
Stereo	representation	of	2|Fo|-|Fc|	electron	density	maps,	contoured	at	1	σ,	covering	all	
atoms	of	the	inhibitors	in	each	of	the	two	independent	USP7	molecules	of	the	asymmetric	
unit.	Protein	is	shown	as	in	Fig.	2a,	and	compound	carbon	atoms	are	in	yellow.	a,	FT671;	b,	
FT827;	c,	FT827	in	an	orientation	to	show	the	covalent	linkage	between	inhibitor	and	
Cys223.			
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Extended	Data	Figure	4.	Schematic	of	FT671	and	FT827	interactions	with	USP7.		
Compound	interactions	and	surrounding	residues	are	labelled,	hydrogen	bonds	indicated,	
and	residues	shown	according	to	their	chemical	properties	(see	legend).	The	images	were	
generated	with	Molecular	Operating	Environment	(MOE)	(v.	2013.08,	Montreal,	Canada).	a,	
FT671;	b,	FT827.		
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Extended	Data	Figure	5.	Molecular	basis	for	USP7	compound	specificity.		
a,	Superposition	of	USP7-FT671	complex	with	indicated	DUBs.	Shown	are	the	isolated	
cartoon	structures	superimposed	in	Fig.	3a	and	3b.	USP7	apo	and	USP7-FT671	(top	left)	
show	an	identical	switching	loop	position,	whereas	the	corresponding	region	in	other	apo	
USP	structures	is	in	a	distinct	conformation	that	resembles	the	USP7~Ub	complex	(see	Fig.	
3a,	b).	Structures	displayed:	USP7	apo,	PDB	1NB8	24;	USP4	apo,	PDB	2Y6E	40;	USP8	apo,	PDB	
2GFO	41;	USP12	apo,	PDB	5K16	42;	USP14	apo,	PDB	2AYN	43.	b,	Binding	site	detail,	showing	
the	interactions	between	Palm	domain	Tyr	residues	(Tyr465	and	Tyr514	in	USP7)	and	the	
Thumb	domain	and	switching	loop	backbone	present	in	all	USP	apo	structures.	The	USP7	
apo	switching	loop	conformation	disallows	the	Tyr465	interaction,	which	rotates	away	from	
the	Thumb	domain,	and	allows	Tyr514	to	adopt	a	buried	conformation	(Tyr514	‘down’	
position).	This	generates	space	for	compound	binding.	In	other	USP	apo	structures,	the	
equivalent	Tyr	residues	form	hydrogen	bonds	with	the	switching	loop	and	occupy	the	
compound	binding	site.				
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Extended	Data	Figure	6.	Characterisation	of	compound	resistant	USP7	mutants.			
a-c,	SPR	based	binding	of	FT671	(a),	FT827	(b)	and	ubiquitin	(c)	to	indicated	USP7	mutants.	
For	compound	binding	to	wild-type	USP7CD	and	Akt-PH	controls,	see	Extended	Data	Fig.	1b.		
Sensorgrams	are	plotted	showing	two	technical	replicates.	These	data	are	representative	of	
three	biological	replicates.	Error	range	in	c	represents	standard	deviation	of	the	mean.	d,	
Summary	table	of	binding	constants	observed	for	experiments	in	Extended	Data	Fig.	1b	and	
6a-c.	Biological	repeats	are	indicated	(n=9	for	USP7CD	WT,	n=3	for	USP7CD	mutants),	and	
errors	indicate	the	standard	error	of	the	mean	range	observed.	e,	Circular	dichroism	profiles	
of	USP7CD	WT	(red),	USP7CD	F291N	(orange),	USP7CD	Q297A	(green),	and	USP7CD	Y465N	
(blue);	each	experiment	was	performed	in	triplicate.	f,	Tabulated	values	for	experiments	
shown	in	Fig.	3f.	SEM,	standard	error	of	the	mean.	g,	Structure	of	activated	USP7.	The	
switching	loop	in	USP7	is	a	point	of	intrinsic	allosteric	regulation,	provided	by	a	C-terminal	
module	of	five	ubiquitin-like	domains	(termed	HUBL1	to	HUBL5)	followed	by	an	activation	
peptide	(aa	1084-1102)26	(see	Extended	Data	Fig.	1a).	In	full-length	USP7,	the	activation	
peptide	stabilises	the	active	conformation	of	the	switching	loop	in	the	ubiquitin	bound	
state26-28,	and	this	can	be	modulated	by	USP7	activating	proteins	such	as	GMPS26,29.	Shown	
is	the	structure	of	activated	USP7	bound	to	its	C-terminal	activation	peptide.	The	model	was	
generated	from	PDB	5JTV	27,	and	shown	are	the	catalytic	domain	with	ubiquitin	in	the	S1	
site	(coloured	as	in	Fig.	2a)	of	molecule	1	in	the	asymmetric	unit,	and	the	HUBL5	domain	
and	activation	peptide	(orange)	of	molecule	2	in	the	asymmetric	unit,	which	in	the	crystal	
binds	to	molecule	1	in	trans.	Uncropped	images	for	gels	are	shown	in	Supplementary	Figure	
1.	
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Extended	Data	Figure	7.	USP7	knockdown	or	inhibitors	affect	USP7	substrates	in	cell	lines.	
a,	HCT116	cells	were	transfected	with	non-targeting	control	(NT1)	or	three	different	USP7-
targeting	siRNAs	for	72	h,	harvested	and	probed	with	indicated	antibodies.	A	representative	
experiment	from	two	biological	replicates	is	shown.	b,	U2OS	cells	transfected	with	a	pool	of	
4	independent	siRNAs	targeting	USP7	or	a	non-targeting	control	siRNA,	as	in	a.	A	
representative	experiment	from	two	biological	replicates	is	shown.		c,	HCT116	cells	were	
treated	with	10	µM	FT671	for	24	h	and	RNA	was	extracted	for	real-time	PCR	measurements	
with	primer	sets	against	indicated	transcripts	(see	Methods).	Data	were	analysed	with	the	
delta-CT	method.	Experiments	were	performed	in	triplicate.	d,	HCT116	cells	were	treated	
with	FT671	(10	µM)	for	indicated,	longer	periods,	harvested	and	probed	with	indicated	
antibodies.	A	representative	experiment	from	two	biological	replicates	is	shown.	e,	
Experiment	as	in	Fig.	4d,	with	higher	FT671	concentration.	p53	levels	are	upregulated	upon	
FT671	treatment	in	cells	expressing	USP7	WT,	but	not	in	cells	expressing	compound	
resistant	mutants.	USP7	expression	was	induced	for	7	h	by	1	µg/mL	doxycycline,	and	cells	
were	treated	for	4	h	with	3	µM	FT671.	f,	IMR-32	neuroblastoma	cells33	were	treated	with	
indicated	concentrations	of	FT671,	and	effects	on	p53	and	N-Myc	levels	were	tested	by	
Western	blotting.	A	representative	experiment	from	two	biological	replicates	is	shown.	g,	h,	
HCT116	(g)	or	MM.1S	(h)	cells	were	treated	for	indicated	times	with	FT671,	and	Western	
blotted	for	UHRF1	and	DNMT1.	Vinculin	and	actin	serve	as	loading	controls.	A	
representative	experiment	from	two	biological	replicates	is	shown.	Uncropped	images	for	
gels	are	shown	in	Supplementary	Figure	1.	
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Extended	Data	Figure	8.	Characterisation	of	FT671	effects	in	vivo.				
a,	MM.1S	cells	were	treated	for	the	indicated	times	with	10	μM	FT671,	and	proteins	
detected	by	Western	blotting	with	indicated	antibodies	(see	Methods).	A	representative	
experiment	from	two	biological	replicates	is	shown.	b,	Meso	Scale	analysis	(see	Methods)	
measuring	the	ratio	of	ubiquitinated	versus	non-ubiquitinated	MDM2	in	MM.1S	cells	upon	
FT671	treatment	and	proteasome	inhibition	(25	µM	MG132).	c,	MM.1S	cells	were	treated	
with	10	µM	FT671	for	the	indicated	times	and	RNA	was	extracted	for	real-time	PCR	
measurements	with	primer	sets	against	indicated	transcripts	(see	Methods).	Data	were	
analysed	with	the	delta-CT	method.	Experiments	were	performed	in	duplicate.	d,	qPCR	
analysis	as	in	c	using	a	single	time	point	against	MCL1	and	c-Myc,	which	in	this	setting	are	
not	p53	target	genes	after	24	h	of	10	µM	FT671.	Experiments	were	performed	in	triplicate.	
e,	MM.1S	tumour	xenograft	tissues	were	analysed	for	p53	expression	by	Western	blotting	
and	normalised	for	β-actin	loading	control.	Uncropped	images	for	gels	are	shown	in	
Supplementary	Figure	1.	 	
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Extended	Data	Table	1.	FT671	and	FT827	specificity.		
Tabulated	specificity	data	of	FT671	and	FT827	at	50	µM	against	a	panel	of	named	DUBs	of	
different	families,	graphically	depicted	in	Fig.	1b.	(1)	+Ubiquitin@Kd;	(2)	+Ubiquitin@Bmax;	
(3)	Proteasome-VS@Kd;	(4)	USP10	and	USP47	were	tested	individually	at	25	μM	FT671;	N.D.	
,	not	determined.	
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Extended	Data	Table	2.	Data	collection	and	refinement	statistics.		
Values	in	parentheses	are	for	the	highest	resolution	shell.	All	datasets	were	collected	from	a	
single	crystal	each.	
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Extended Data Table 1
 
FT671  FT827  
USP enzymes  
  
USP1/UAF1  103  101  
USP2  101  98 
USP4  96  93 
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USP5 (1)  112  104  
USP5 (2)  110 92 
USP6  96 95 
USP7  0 14 
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USP30  103 112  
USP35  103  93 
USP36  89 117  
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JOSD1  96  91 
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USP10 (4) 99  N.D.
USP47 (4) 95 N.D.
Extended Data Table 2
USP7~FT671 USP7~FT827
Data collection
Cell dimensions
Space Group
α, β, γ (º)
a, b, c (Å)
Rmeas
Resolution (Å)
CC1/2
< I/σI >
Redundancy
Completeness (%)
Renement
No. reections
Resolution (Å)
No. atoms
Rwork / Rfree
Ligand
Protein
B factors
Water
Ligand
Protein
R.m.s deviations
Water
Bond angles (º)
Bond length (Å)
P21
90.0, 97.2, 90.0
71.3,  70.3, 78.6
0.063 (0.856)
77.95 - 2.35 (2.39 - 2.35)
14.9 (2.0)
3.3 (3.4)
96.6 (97.3)
P1
105.1, 107.9, 113.0
62.8, 63.3, 65.7
0.068 (0.651)
52.50 - 2.33 (2.39 - 2.33)
0.993 (0.811)
10.9 (2.1)
2.7 (2.8)
97.0 (96.4)
31606
50.00 - 2.33
0.188 / 0.247
78
5083
18
65.0
77.5
64.6
1.566
0.014
Data collection and renement statistics
0.994 (0.588)
29654
0.215 / 0.272
5004
48
63.4
53.7
54.0
0.014
1.575
76
50.00 - 2.35
Extended Data Figure 1
0 600 1200 1800 2400 3000 3600
2000
4000
6000
8000
10000
USP7C-term with FT827 
Time (s)
0.0000
0.0002
0.0004
0.0006
FT827 k
obs plot
[Compound] (μM)
k o
bs
(s-1
)
0.04
0.08
0.15
0. 3
0. 6
1. 5
3
6
12
24
48
[FT827] (μM)
a
b
c
d
IC50 FT671
[FT671] (nM)
USP7CD       52 (29-94) nM 
USP7C-term  69 (39-120) nM 
Catalytic Domain UBL1 UBL2 UBL3 UBL4 UBL5208 1102USP7C-term
Catalytic Domain208 560USP7CD
TRAF Catalytic Domain UBL1 UBL2 UBL3 UBL4 UBL5 11021USP7FL
0 10 20 30 40 50
RF
U
-60 0 60 120 180 240 300 360
0
5
10
15
20
Time (s)
FT827 - USP7CD
-60 0 60 120 180 240 300 360
0
5
10
15
20
Time (s)
FT827 - AktPH
Kd  7.8 (5.9 - 10.2) μM
kinact       0.0003 ± 0.0001 s-1 
KI   4.2 ± 1.5 μM 
kinact / KI      66 ± 25 M-1 s-1
-60 0 60 120 180 240 300 360
0
5
10
15
Time (s)
FT671 - AktPH
Re
sp
on
se
 (R
U)
-60 0 60 120 180 240 300 360
0
5
10
15
Time (s)
FT671 - USP7CD
Kd 65 (45 - 92) nM
0.1 10 1000 100,000
-20
0
20
40
60
80
100
120
%
 In
hi
bi
tio
n
Extended Data Figure 2
FT671 (extract) FT671 (in cell)
HA-UbC2Br 
FT827 (μM)
FT827 (extract)
0
-
0
+
0.1
+
0.3
+
1
+
3
+
10
+
30
+
HA-UbC2Br 
FT671 (μM) 0
-
0
+
0.1
+
0.3
+
1
+
3
+
10
+
30
+ HA-UbC2Br 
FT671 (μM) 0
-
0
+
0.1
+
0.3
+
1
+
3
+
10
+
30
+
HA-UbC2Br 
FT827 (μM)
FT827 (in cell)
0
-
0
+
0.1
+
0.3
+
1
+
3
+
10
+
30
+
250 -
150 -
100 -
75 -
50 -
37 -
20 -
15 -
10 -
25 -
anti-HA
USP7~UbC2Br
USP7~UbC2Br
anti-β-actin
250 -
150 -
100 -
75 -
50 -
37 -
20 -
15 -
10 -
25 -
250 -
150 -
100 -
75 -
50 -
37 -
20 -
15 -
10 -
25 -
anti-HA
USP7~UbC2Br
anti-β-actin
FT671 FT827Ctrl
Input
HA-UbC2Br IP
+ + + + +
anti-HA
anti-β-actin
USP7~UbC2Br
USP7
-
-
Inhibitor
[μM]
+ + + + +
- 1 1 1010
anti-β-actin anti-β-actin
anti-HA anti-HA
USP7~UbC2Br
MS
HA-UbC2Br
IP
WB
Compounds
Compounds
Intact cells
(in situ)
Cell 
extracts
Lysis
a
d e
b c
f
250 -
150 -
100 -
75 -
50 -
37 -
20 -
15 -
25 -
10 -
250 -
150 -
100 -
75 -
50 -
37 -
20 -
15 -
25 -
150 -
50 -
anti-USP7
USP7~UbC2Br
P22077
+
+
50
g
FT827 FT671 
0
-
0
+
0.3
 +
3
+
30
 +
0
+
0.3
 +
3
+
30
 +
P22077 
0
+
0.3
 +
3
+
30
 +
FT827 FT671 
0
-
0
+
0.3
 +
3
+
30
 +
0
+
0.3
 +
3
+
30
 +
P22077 
0
+
0.3
 +
3
+
30
 +HA-UbC2Br 
Compound (μM) 
USP7-UbC2Br
USP7
anti-β-actin
anti-HA
USP7~UbC2Br
250 -
150 -
100 -
75 -
50 -
37 -
20 -
15 -
10 -
25 -
5 min reaction with probe 60 min reaction with probe
anti-USP7
Extended Data Figure 3
a
b USP7~FT827 (2.33 Å)
USP7-FT671 (2.35 Å)
molecule A
molecule B
molecule A
molecule B
molecule A molecule B
c USP7~FT827 (2.33 Å)
FT827 Cys223 FT827
Cys223
FT827
Cys223
FT827
Cys223
FT827
Cys223
FT827
Cys223
FT671 FT671
FT671 FT671
Extended Data Figure 4
a
b USP7~FT827
USP7-FT671 
Extended Data Figure 5
USP7-FT671 vs. USP7 apo (1NB8) USP7-FT671 vs. USP4 apo (2Y6E) USP7-FT671 vs. yUBP6 apo (1VJV)
USP7-FT671 vs. USP8 apo (2GFO) USP7-FT671 vs. USP12 apo (5K16) USP7-FT671 vs. USP14 apo (2AYN)
USP7 apo vs. USP7-FT671
Tyr465
Tyr514
‘down’
Switching 
loop
(Thumb)
(Palm)
FT671
USP7 apo vs. USP4 apo
Tyr882
(Thumb)
(Palm)
Tyr916 ‘up’
USP7 apo vs. USP8 apo
Tyr1068
(Thumb)
(Palm)
Tyr1102 ‘up’
USP7 apo vs. USP12 apo
Tyr318
(Thumb)
(Palm)
Tyr362 ‘up’
USP7 apo vs. USP14 apo
Tyr435
(Thumb)
(Palm)
Tyr475 ‘up’
(Blocking 
loop ‘in’)
a
b
Extended Data Figure 6
Fingers
Thumb
Palm
cat. triad
(aligned)
Ub in S1 site
HUBL5 
activation peptide in 
Switching loop pocket 
USP7 bound to C-terminal activation peptide (PDB 5JTV)
USP7 CD
WT 0.31 ± 0.029 0.39 ± 0.014
F291N 0.25 ± 0.018 1.33 ± 0.035
Q297A 0.68 ± 0.095 0.062 ± 0.0043
Y465N 0.46 ± 0.030 0.0062 ± 0.00018
 kcat ± SEM (min-1)KM ± SEM (μM) 
360 360
0
5
10
15
-60 0 60 120 180 240 300
Time (s)
USP7CD F291N - FT671 
Kd = N.D.
0
5
10
15
Re
sp
on
se
 (R
U)
-60 0 60 120 180 240 300
Time (s)
USP7CD Q297A - FT671
Kd  = N.D.
-60 0 60 120 180 240 300 360
0
5
10
15
Time (s)
USP7CD Y465N - FT671 
-60 0 60 120 180
0
50
100
150
Time (s)
Re
sp
on
se
 (R
U)
USP7CD WT - ubiquitin 
Kd = 280 μM(270-300 μM)
-60 0 60 120 180
0
50
100
150
Time (s)
USP7CD Q297A - ubiquitin 
Kd = 330 μM(310-350 μM)
-60 0 60 120 180
0
50
100
Time (s)
USP7CD F291N - ubiquitin
Kd = 190 μM(170-210 μM)
-60 0 60 120 180
0
1
2
3
4
5
Time (s)
AktPH - ubiquitin
Kd = N.D.
-60
0
5
10
15
20
0 60 120 180 240 300 360
Time (s)
0
5
10
15
20
-60 0 60 120 180 240 300 360
Time (s)
USP7CD Q297A - FT827 USP7CD F291N - FT827
Kd  = N.D. Kd  = N.D.
Re
sp
on
se
 (R
U)
a
c
-60 0 60 120 180 240 300 360
0
5
10
15
20
Time (s)
USP7CD Y465N - FT827
Kd = N.D.
Kd  = N.D.
b
Re
sp
on
se
 (R
U)
-60 0 60 120 180
0
50
100
150
200
250
Time (s)
USP7CD Y465N - ubiquitin
Kd in μM (SEM range) 
USP7CD FT827 FT671 Ubiquitin
WT (n=9) 7.8 (5.9-10.2) 0.065 (0.045-0.092) 280 (270-300)
F291N (n=3) No binding No binding 190 (170-210)
Q297A (n=3) No binding No binding 330 (310-350)
Y465N (n=3) No binding No binding 250 (240-270)
f
Kd = 250 μM(240-270 μM)
e
g
M
ea
n 
Re
sid
ue
 El
lip
tic
ity
 (d
eg
 cm
2  
dm
ol
-
1 )
200 220 240
-10000
-5000
0
5000
10000
15000
WT
F291N
Q297A
Y465N
USP7CD 
 (nm)d
Extended Data Figure 7
a b
HCT116
d
U2OS
NT
1
siU
SP
7p
150
52
24
52
p53
β-Actin
p21
USP7
NT
1
M
oc
k 
#7 #8#6 NT
1
siUSP7 (72 h)
u
n
tre
at
ed
USP7
p53
β-Actin
p21
52
40
150
17
4 
h
24
 h
48
 h
DM
SO
 (9
6 h
)
10 μM FT671
DM
SO
 (2
4 h
)
72
 h
96
 h
MDM2
p53
β-Actin
USP7
p21
3 μM FT671 (4 h)
p53
β-Actin
USP7
GFP
FT671 +
WT
+
Q297A
+
F291N
+
DMSO + + + +
HCT116 Flp-In TRex
52
150
52
UHRF1
β-Actin
0 0.5 2 4 8 24 h
FT671 (10 μM)
DNMT1
f g
-100
-40
-150
0 0.5 2 4 8 24 h
FT671 (10 μM)
Vinculin
MM.1S
-150
UHRF1
β-Actin
DNMT1
48
-40
-140
-100
HCT116
h
NT
FT6
71
 
(24 
h, 1
0 μM
)
c
e
0
1
2
3
4
5
6
HCT116
Fo
ld
 C
ha
ng
e 
CDKN1A
Myc
MCL1
HCT116
GFP-USP7
10
 μ
M
3 
μ
M
DM
SO
FT671 (20 h)
p53
Actin
N-Myc
56
56
43
IMR-32
85
52
20
150
38
Extended Data Figure 8
Vehicle
p53
β-Actin
200 mg kg-1
0.5 h 2 h 6 h
Vehicle
p53
β-Actin
75 mg kg-1
p53
β-Actin
Vehicle 25 mg kg-1
p53
β-Actin
Vehicle 200 mg kg-1 75 mg kg-1 25 mg kg-1 24 h
e
c
20 -
37 -
0 2 4 8 24 h
50 - p53
p21
FT671 (10 μM)
a
MM.1S
β-Actin
0 1 2 3 4 5 6 7 8
0
1
2
3
MM.1S, FT671 (10 μM), MG132 (25 μM)
treatment time (h)
Ub
q 
/ t
ot
al 
M
DM
2
 
(no
rm
ali
sed
 to
 DM
SO
)
b
NT
0
1
2
3
4
5
6
Fo
ld
 C
ha
ng
e 
CDKN1A
Myc
MCL1
MM.1S
FT6
71
 
(24 
h, 1
0 μM
)
d
0 4 8 12 16 20 24
0
2
4
6
8
time (h)
Re
lat
ive
 Q
u
an
tit
at
io
n
CDKN1A
BBC3
MDM2
RPS27L
MM.1S, FT671 (10 μM)
Figure 5
a b
c d
1 5
days treatment
10 15 20
Tu
m
ou
r v
ol
um
e (
mm
3 )
(M
ea
n +
/- S
D; 
n=
9)
MM.1S xenograft 
0
vehicle
200 mg/kg FT671
100 mg/kg FT671
1000
2000
3000
***
***
*
MM.1S
Veh
icle 0.5
 h 2 h 6 h 24
 h
p5
3 (
% 
of 
ve
hic
le s
ign
al)
(M
ea
n +
/- S
D; 
n=
5)
200 mg kg-1 FT671
(single dose)
0
100
200
300
*
**
**
p=0.147
MM.1S xenograft 
10-10 10-9 10-8 10-7 10-6 10-5
0
20
40
60
80
100
log [FT671] M
%
 in
hi
bi
tio
n 
of
 vi
ab
ilit
y
p=0.0153 
p=0.0029 
p=0.0095 
days after inoculation
Vehicle
200 mg kg-1 FT671
100 mg kg-1 FT671
15 20 25 30 35
Bo
dy
 w
ei
gh
t (%
 of
 D
15
)
(M
ea
n +
/- S
D; 
n=
9)
0
25
50
75
100
125
MM.1S xenograft 
1	
	
	
Molecular	basis	of	USP7	inhibition	by	selective	small	molecule	
inhibitors	
Andrew	P.	Turnbull	et	al.,		
	
SUPPLEMENTARY	INFORMATION	
	
1. Inventory	
	
1.1	Supplementary	data	files:	
- Supplementary	Figure	1	
Annotated	full	gel	blots	for	all	figures	in	the	main	manuscript	
	
- Supplementary	Table	1	
DUBs	identified	by	mass	spectrometry	after	HA-UbC2Br	labelling	of	MCF7	cell	extracts	
	
- Supplementary	Table	2	
All	proteins	identified	by	mass	spectrometry	after	HA-UbC2Br	labelling	of	MCF7	cell	extracts	
	
- Supplementary	Table	3	
Sequences	for	any	RNAi/small	RNA	constructs	used	in	this	study	
	
- Supplementary	Source	Data	Fig	3	
- Supplementary	Source	Data	Fig	4	
- Supplementary	Source	Data	Fig	5	
- Supplementary	Source	Data	Fig	E1	
- Supplementary	Source	Data	Fig	E6	
- Supplementary	Source	Data	Fig	E7	
- Supplementary	Source	Data	Fig	E8	
	
- Supplementary	Chemistry	Data	
Analytical	data	for	the	synthesis	of	USP7	inhibitors	
	
	
	
1.2 Chemical	synthesis	of	USP7	compounds	
	 	
2	
	
Chemical	synthesis	of	USP7	compounds		
	
General	
1H,	13C	and	19F	nuclear	magnetic	resonance	(NMR)	spectra	were	obtained	on	either	Bruker	or	Varian	
spectrometers	at	300	or	400	MHz,	respectively.	Spectra	are	given	in	ppm	(δ)	using	the	residual	peak	of	
the	solvent	as	internal	standard	(DMSO-d6:	2.50	ppm	(1H)	/	39.5	ppm	(13C);	CD3OD:	3.31	ppm	(1H)	or	
tetramethylsilane	(TMS)	as	internal	standards.	and	coupling	constants,	J,	are	reported	in	Hertz.	Mass	
spectra	were	collected	using	a	Waters	ZQ	Single	Quad	Mass	Spectrometer	(ion	trap	electrospray	
ionization	(ESI)).		Purity	and	low	resolution	mass	spectral	data	were	measured	using	Waters	Acquity	i-
class	ultra-performance	liquid	chromatography	(UPLC)	system	with	Acquity	Photo	Diode	Array	Detector,	
Acquity	Evaporative	Light	Scattering	Detector	(ELSD)	and	Waters	ZQ	Mass	Spectrometer.	Data	was	
acquired	using	Waters	MassLynx	4.1	software	and	purity	characterized	by	UV	wavelength	220	nm,	
evaporative	light	scattering	detection	(ELSD)	and	electrospray	positive	ion	(ESI).	(Column:	Acquity	UPLC	
BEH	C18	1.7µm	2.1	X	50	mm;	Flow	rate	0.6mL/min;	Solvent	A	(95/5/0.1%:	10mM	Ammonium	
Formate/Acetonitrile/Formic	Acid),	Solvent	B	(95/5/0.09%:	Acetonitrile/Water/Formic	Acid);	gradient:	5-
100%	B	from	0	to	2mins,	hold	100%B	to	2.2mins	and	5%B	at	2.21mins.		The	absolute	configuration	of	
FT671	was	assigned	by	X-Ray	crystallography	
	
	
1.	Preparation	of	FT827	
2'-aminobiphenyl-4-carboxylic	acid	
	
A	250-mL	round-bottom	flask	fitted	with	a	nitrogen	balloon,	magnetic	stir	bar,	condenser	and	
thermometer	was	charged	with	2-bromoaniline	(2	g,	11.63	mmol),	dioxane	(40	mL),	water	(4	mL),	K3PO4	
(7.6	g,	35.80	mmol),	4-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic	acid	(3.2	g,	12.84	mmol)	and	1,1'-
bis(diphenylphosphino)ferrocene	palladium(II)	chloride	complex	with	dichloromethane	(0.76	g,	0.94	
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mmol).		The	resulting	solution	was	stirred	for	10	h	at	100	°C	under	nitrogen.		The	reaction	mixture	was	
cooled	to	25	°C.		The	pH	of	the	mixture	was	adjusted	to	5	with	hydrochloric	acid	(6	N).		The	product	was	
extracted	with	dichloromethane	(2	x	30	mL).	The	organic	layers	were	combined,	dried	over	anhydrous	
sodium	sulfate,	filtered	and	concentrated	under	vacuum	to	afford	2'-aminobiphenyl-4-carboxylic	acid	
(0.8	g,	32%).		LCMS:	(ES)	m/z	214	[M+H].		
5-((4-hydroxypiperidin-4-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one),	 trifluoroacetic	
acid	salt	
	
Step	1.	5-Amino-1-methyl-1H-pyrazole-4-carboxamide	
A	500-mL	3-necked	round-bottom	flask	fitted	with	a	magnetic	stir	bar	and	thermometer	was	charged	
with	sulfuric	acid	(120	mL),	followed	5-amino-1-methyl-1H-pyrazole-4-carbonitrile	(52	g,	426	mmol)	in	
portions	at	0	°C.	Upon	completion	of	the	addition,	the	reaction	mixture	was	warmed	to	room	
temperature	and	stirred	for	1	h.	The	reaction	quenched	with	sodium	hydroxide	(50%	wt	solution	in	
water)	and	the	pH	of	the	mixture	was	adjusted	to	8.		The	solids	were	collected	by	filtration,	washed	with	
water	(3	x	50	mL)	and	dried	in	an	oven	to	provide	5-amino-1-methyl-1H-pyrazole-4-carboxamide	(50	g,	
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Step	2.	1-Methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one	
A	500-mL	3-necked	round-bottom	flask	fitted	with	a	magnetic	stir	bar,	condenser	and	thermometer	was	
charged	with	5-amino-1-methyl-1H-pyrazole-4-carboxamide	(Step	1,	50	g,	357	mmol),	
(diethoxymethoxy)ethane	(120	mL)	and	acetic	anhydride	(120	mL).	The	solution	was	stirred	for	1	h	at	
130	°C	in	an	oil	bath.		The	reaction	mixture	was	allowed	to	cool	to	0	°C.		The	solids	were	collected	by	
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filtration,	washed	with	n-hexane	(3	x	50	mL)	and	dried	in	an	oven	to	provide	to	1-methyl-1H-
pyrazolo[3,4-d]pyrimidin-4(5H)-one	(51	g,	95%).		LCMS:	(ESI)	m/z	151	[M+H].	
Step	3.	Tert-butyl4-hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5	
(4H)-yl)methyl)piperidine-1-carboxylate	
A	500-mL	3-necked	round-bottom	flask	fitted	with	a	magnetic	stir	bar,	condenser	and	thermometer	was	
charged	with	1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one	(Step	2,	20	g,	133	mmol),	N,N-
dimethylformamide	(150	mL),	tert-butyl	1-oxa-6-azaspiro[2.5]octane-6-carboxylate	(31	g,	146	mmol),	
Cs2CO3	(130	g,	399	mmol).		The	reaction	mixture	was	stirred	for	2	h	at	80	°C	in	an	oil	bath.	After	cooling	
to	room	temperature,	the	reaction	was	quenched	with	water	(300	mL).		The	product	was	extracted	with	
ethyl	acetate	(4	x	200	mL).		The	combined	organic	layers	were	washed	with	brine	(300	mL),	dried	over	
anhydrous	sodium	sulfate,	filtered	and	concentrated	under	vacuum.	The	residue	was	purified	by	column	
chromatography	eluting	with	dichloromethane/methanol	(10:1,	v/v)	to	yield	tert-butyl	4-hydroxy-4-((1-
methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)methyl)piperidine-1-carboxylate	(30	g,	62%).		1H-
NMR	(300MHz,	CDCl3):	δ1.45	(s,	9H),	1.47-1.67	(m,	4H),	3.12-3.19	(m,	2H),	3.96-3.81	(m,	2H),	4.00	(s,	
3H),	4.04-4.18	(m,	2H),	8.02	(s,	1H),	8.07	(s,	1H)	ppm.		13C-NMR	(101	MHz,	CHLOROFORM-d):	δ	ppm	28.4,	
34.3,	35.1,	55.4,	70.3,	79.7,	105.4,	135.1,	149.7,	151.5,	154.6,	158.7.	LCMS:	(ESI)	m/z	364	[M+H].	
Step	4.	5-((4-hydroxypiperidin-4-yl)methyl)-1-methyl-1H-pyrazolo	[3,4-d]pyrimidin-4(5H)-one,	
trifluoroacetic	acid	salt	
A	250-mL	round-bottom	flask	fitted	with	a	magnetic	stir	bar	was	charged	with	tert-butyl	4-hydroxy-4-
((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)	methyl)piperidine-1-carboxylate	(Step	3,	20	g,	
55	mmol),	trifluoroacetic	acid	salt	(20	mL)	 and	dichloromethane	(150	mL).		The	solution	was	stirred	for	
4	h	at	room	temperature	and	concentrated	under	vacuum	to	give	5-((4-hydroxypiperidin-4-yl)methyl)-1-
methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one,	trifluoroacetic	acid	salt	(21	g).		LCMS:	(ESI)	m/z	264	
[M+H].	
N-(4'-(4-hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d]	pyrimidin-5(4H)-yl)methyl)piperidine-1-
carbonyl)biphenyl-2-yl)ethenesulfonamide														
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Step	1.		5-((1-(2'-Aminobiphenylcarbonyl)-4-hydroxypiperidin-4-yl)methyl)-1-	methyl-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one																		
A	100-mL	round-bottom	flask	fitted	with	a	magnetic	stir	bar	was	charged	with	2'-aminobiphenyl-4-
carboxylic	acid	(400	mg,	1.88	mmol),	5-((4-hydroxypiperidin-4-yl)methyl)-1-methyl-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one,	trifluoroacetic	acid	salt	(800	mg,	2.12	mmol)		1-[Bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium	3-oxid	hexafluorophosphate)	(857	mg,	2.25	mmol),	N,N-
diethylisopropylamine	(970	mg,	7.51	mmol)	and	dichloromethane	(30	mL).		The	resulting	solution	was	
stirred	for	2	h	at	25	°C	and	then	diluted	with	water	(30	mL).	The	product	was	extracted	with	
dichloromethane	(3	x	30	mL).		The	combined	organic	layers	were	dried	over	anhydrous	sodium	sulfate,	
filtered	and	concentrated	under	vacuum.		The	residue	was	purified	by	preparatory	thin	layer	
chromatography	eluting	with	ethyl	acetate	to	afford	5-((1-(2'-aminobiphenylcarbonyl)-4-
hydroxypiperidin-4-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one	(220	mg,	26%).		LCMS:	
(ESI)	m/z	459[M+H].																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
Step	2.		N-(4'-(4-hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)	-yl)methyl)piperidine-
1-carbonyl)biphenyl-2-yl)ethenesulfonamide	(FT827)																																		
A	100-mL	3-necked	round-bottom	flask	fitted	with	a	nitrogen	balloon,	magnetic	stir	bar	and	
thermometer	was	charged	with	5-((1-(2'-aminobiphenylcarbonyl)-4-hydroxypiperidin-4-yl)methyl)-1-
methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one	(Step	1,	40	mg,	0.09	mmol),	dichloromethane	(5	mL)	and	
triethylamine	(30.7	mg,	0.30	mmol).			A	solution	of	2-chloroethane-1-sulfonyl	chloride	(17	mg,	0.10	
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mmol)	in	dichloromethane	(1	mL)	was	added	in	portions	at	0	°C.		The	resulting	solution	was	stirred	for	
0.5	h	at	0	°C	and	then	concentrated	under	vacuum.		The	residue	was	purified	by	preparatory	HPLC*	to	
give	N-(4'-(4-hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)methyl)piperidine-1-
carbonyl)biphenyl-2-yl)ethenesulfonamide	as	a	white	solid	(11	mg,	21%).	*Column:	X	bridge	prep	shield	
RP18	OBD	Column	19	x	150	nm,	5	µM	Mobile	phase	A:	water	(0.05%	NH4HCO3)/Mobile	phase	B:	
acetonitrile.		Flow	rate:	20	mL/min.	Gradient:	16%	B	to	42%	B	over	7	min.		Detector:	220	and	254	nm	
(Supplementary	Chemistry	Data	a).	
	
High-resolution	mass	spectrometry	(HRMS):	(C24H23F4N7O3	–	expected	[M+H]+	549.19201,	observed	
[M+H]+	549.19150	(0.93	ppm)	(Supplementary	Chemistry	Data	b).	Agilent	QTOF	6560	LC-MS	ESI+	mode.	
Column:	Waters	Acquity	UPLC	BEH	C18,	1.7	um,	2.1	x	50	mm.	Mobile	phase	A:	95%	Water/5%	
Acetonitrile	with	0.1%	Formic	Acid	in	10	mM	Ammonium	Formate/Mobile	phase	B:	95%	Acetonitrile/5%	
Water	with	0.09%	Formic	Acid.		Flow	rate:	20	mL/min.	Column	temperature:		35	°C.	Gradient:	5-100%	B	
in	2.0	min,	hold	100%	to	2.2	min.	LC	Flow	Rate:	0.6	mL/min.	Detector:	220	nm.	
	
1H-NMR	(400MHz,	CD3OD)	δ	1.46-1.64	(m,	1H),	1.68-1.87	(m,	3H),	3.46-3.49	(m,	2H),	3.68-3.72	(m,	1H),	
3.99	(s,	3H),	4.12-4.21	(m,	2H),	4.38-4.41	(m,	1H),	5.88	(d,	J	=	10.0Hz,	1H),	6.06	(d,	J	=	16.8Hz,	1H),	6.50-
6.54	(m,	1H),	7.31-7.40	(m,	3H),	7.46-7.56	(m,	5H),	8.06	(s,	1H),	8.28	(s,	1H)	ppm	(Supplementary	
Chemistry	Data	c).				
13C-NMR	(101	MHz,	CHLOROFORM-d): δ ppm	34.3,	55.9,	70.4,	105.4,	119.8,	124.9,	128.0,	128.5,	129.2,	
129.4,	130.7,	132.1,	133.4,	135.1,	135.4,	135.8,	139.0,	149.4,	151.5,	158.9,	169.6	(Supplementary	
Chemistry	Data	d,e).		
	
	
2.	Preparation	of	FT671	
4,4-difluoro-3-(1H-pyrazol-1-yl)butanoic	acid		
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Step	1.		Ethyl	4,4-difluoro-3-oxobutanoate	
A	500-mL	round-bottom	flask	was	charged	with	sodium	ethoxide	(28.3	g,	416	mmol)	and	
ethanol	(80	mL)	followed	by	the	addition	of	a	solution	of	ethyl	2,2-difluoroacetate	(43	g,	347	
mmol)	in	ethyl	acetate	(170	mL)	added	slowly	with	stirring	at	room	temperature.		The	resulting	
solution	was	stirred	for	2	h	at	60	°C.		Upon	cooling	to	room	temperature,	the	reaction	was	
quenched	by	the	addition	of	hydrochloric	acid	(aqueous	6N,	150	mL)	and	the	pH	of	the	solution	
was	adjusted	to	4-5.		The	resulting	solution	was	extracted	with	ethyl	acetate	(3	x	200	mL)	and	
the	organic	layers	were	combined	and	dried	over	anhydrous	sodium	sulfate	and	concentrated	
under	vacuum	to	afford	ethyl	4,4-difluoro-3-oxobutanoate	which	was	used	in	Step	2	without	
further	purification	(29	g).		GCMS	m/z	166.	
Step	2.			Ethyl	4,4-difluoro-3-hydroxybutanoate	
A	500-mL	round-bottom	flask	was	charged	with	crude	ethyl	4,4-difluoro-3-oxobutanoate	(Step	
1,	8	g,	96	mmol),	toluene	(250	mL)	and	sodium	borohydride	(2.38	g,	64.63	mmol).		The	resulting	
solution	was	stirred	for	2	h	at	65	°C.		The	reaction	was	then	quenched	by	the	addition	of	water	
(100	mL).		The	resulting	solution	was	extracted	with	ethyl	acetate	(3	x	50	mL)	and	the	organic	
layers	were	combined,	washed	with	brine,	dried	over	anhydrous	sodium	sulfate	and	
concentrated	under	vacuum.		The	residue	was	purified	by	column	chromatography	eluting	with	
ethyl	acetate/petroleum	ether	(1:5	to	1:2	v/v)	to	afford	ethyl	4,4-difluoro-3-hydroxybutanoate	
(6.8	g,	35%	over	2	steps).		GCMS	m/z	168.			
Step	3.		(E)-ethyl	4,4-difluorobut-2-enoate	
A	25-mL	round-bottom	flask	was	charged	with	ethyl	4,4-difluoro-3-hydroxybutanoate	(Step	2,	
5g,	48.16	mmol)	and	phosphorus	pentoxide	(3.4	g,	23.62	mmol).		The	resulting	solution	was	
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stirred	for	2	h	at	70	oC	in	an	oil	bath.		The	mixture	was	purified	by	distillation	under	reduced	
pressure	(1	mm	Hg)	and	the	fraction	was	collected	at	100	oC	to	give	(E)-ethyl	4,4-difluorobut-2-
enoate	as	a	colorless	oil	(1.8	g,	25%).		GCMS	m/z	150.	
Step	4.		4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoic	acid	
A	100-mL	round-bottom	flask	was	charged	with	3-fluoro-1H-pyrazole	(102	mg,	1.50	mmol)	and	
tetrahydrofuran	(20	mL)	followed	by	the	addition	of	sodium	hydride	(52	mg,	2.17	mmol)	at	0	°C.		
The	resulting	solution	was	stirred	30	min	at	0	°C	before	adding	(E)-ethyl	4,4-difluorobut-2-
enoate	(Step	3,	150	mg,	1.00	mmol).		The	resulting	solution	was	stirred	16	h	at	room	
temperature.		The	reaction	was	quenched	by	the	addition	of	10	mL	of	water	and	extracted	with	
ethyl	acetate	(30	mL).		The	pH	of	the	aqueous	layer	was	adjusted	to	4-5	with	aqueous	
hydrochloric	acid	(aqueous,	6	N)	and	extracted	with	dichloromethane	(2	x	30	mL).		The	organic	
layers	were	combined,	dried	over	anhydrous	sodium	sulfate	and	concentrated	under	vacuum	to	
give	4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoic	acid	(90	mg)	as	a	yellow	oil	which	was	
used	without	further	purification.		LCMS:	(ESI)	m/z	191	[M+H].	
	
Step	1.		5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carbonitrile	
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2-(Methoxymethylene)malononitrile	(1.00	g,	9.25	mmol),	(4-fluorophenyl)	hydrazine	
hydrochloride	(1.40	g,	8.61	mmol),	triethylamine	(1.66	g,	16.4	mmol)	and	ethanol	(50	mL)	were	
added	to	a	100-mL	round-bottom	flask	fitted	with	a	magnetic	stir	bar	and	condenser.	The	
resulting	solution	was	heated	at	reflux	for	16	h.	The	resulting	mixture	was	concentrated	under	
vacuum.	The	residue	was	purified	by	column	chromatography	eluting	with	
dichloromethane/methanol	(10:1	v/v)	to	give	5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-
carbonitrile	(1.00	g,	57	%).		LCMS:	(ESI)	m/z	203	[M+H].	
Step	2.		5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		
5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide	(Step	1,	900	mg,	4.45	mmol)	was	
added	dropwise	to	sulfuric	acid	(10	mL)	at	0	ºC.	The	resulting	solution	was	stirred	for	2	h	at	
25	ºC.	The	pH	of	the	solution	was	adjusted	to	8	by	the	addition	of	10%	aqueous	sodium	
carbonate.	The	resulting	mixture	was	extracted	with	dichloromethane	(4	x	50	mL)	and	the	
organic	layers	were	combined,	dried	over	anhydrous	sodium	sulfate,	filtered	and	concentrated	
under	vacuum	to	provide	5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide	which	was	
used	in	Step	3	without	further	purification.		LCMS:	(ESI)	m/z	221	[M+H].	
Step	3.		1-(4-Fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one	
5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide	(Step	2,	1.00	g,	4.5	mmol),	triethyl	
orthoformate	(20	mL)	and	acetic	anhydride	(20	mL)	were	added	to	a	100-mL	round-bottom	
flask	fitted	with	a	magnetic	stir	bar	and	condenser.	The	resulting	solution	was	heated	at	reflux	
for	1	h	and	then	concentrated	under	vacuum.	The	solids	were	collected	and	washed	with	
hexane	(3	x	20	mL)	to	afford	1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one	
which	was	used	in	Step	4	without	further	purification.		LCMS:	(ESI)	m/z	231	[M+H].	
Step	4.		tert-Butyl	4-((1-(4-fluorophenyl)-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-
yl)methyl)-4-hydroxypiperidine-1-carboxylate	
1-(4-Fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one	(Step	3,	1.00	g,	4.3	mmol),	
tert-butyl	1-oxa-6-azaspiro[2.5]octane-6-carboxylate	(926	mg,	4.34	mmol),	cesium	carbonate	
(4.30	g,	13.2	mmol)	and	DMF	(50	mL)	were	added	to	a	100-mL	round-bottom	flask	fitted	with	a	
magnetic	stir	bar	and	thermometer.	The	resulting	solution	was	stirred	for	5	h	at	80	ºC.	The	
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resulting	solution	was	diluted	with	water	(50	mL).	The	mixture	was	extracted	with	methyl	tert-
butyl	ether	(5	x	20	mL)	and	the	organic	layers	were	combined,	dried	over	anhydrous	sodium	
sulfate,	filtered	and	concentrated	under	vacuum.	The	residue	was	purified	by	column	
chromatography	eluting	with	dichloromethane/methanol	(50:1	v/v)	to	give	tert-butyl	4-((1-(4-
fluorophenyl)-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-yl)methyl)-4-hydroxypiperidine-
1-carboxylate	(500	mg,	26%).		LCMS:	(ESI)	m/z	444	[M+H].																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
Step	5.		1-(4-Fluorophenyl)-5-((4-hydroxypiperidin-4-yl)methyl)-1,5-dihydro-4H-pyrazolo	[3,4-
d]pyrimidin-4-one	trifluoroacetic	acid	salt	
tert-Butyl	4-((1-(4-fluorophenyl)-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-yl)methyl)-4-
hydroxypiperidine-1-carboxylate	(Step	4,	500	mg,	1.13	mmol),	dichloromethane	(30	mL)	and	
trifluoroacetic	acid	(3	mL)	were	added	to	a	50-mL	round-bottom	flask	fitted	with	a	magnetic	stir	
bar	and	condenser.	The	resulting	solution	was	stirred	for	2	h	at	25	ºC.	The	resulting	mixture	was	
concentrated	under	vacuum	to	give	1-(4-fluorophenyl)-5-((4-hydroxypiperidin-4-yl)methyl)-1,5-
dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one	trifluoroacetic	acid	salt	which	was	used	in	Step	6	
without	further	purification.		LCMS:	(ESI)	m/z	344	[M+H].	
Step	6.		5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-4-
yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one	(FT671)	
To	a	250-mL	round-bottom	flask	was	added	4,4-difluoro-3-(5-fluoro-1H-pyrazol-1-yl)	butanoic	
acid	(2.0	g,	9.61	mmol),	N,N-dimethylformamide	(40	mL),		N-(3-Dimethylaminopropyl)-Nʹ-
ethylcarbodiimide	hydrochloride	(2.4	g,	12.5	mmol),		Hydroxybenzotriazole	(1.7	g,	12.6	mmol),	
N,N-diethylisopropylamine	(3.7	g,	28.6	mmol),	1-(4-fluorophenyl)-5-((4-hydroxypiperidin-4-
yl)methyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one,	trifluoroacetic	acid	salt	(Step	5,	4.4	
g,	9.6	mmol).	The	resulting	solution	was	stirred	for	1	h	at	22	°C.	The	reaction	was	poured	into	
200	mL	of	water	and	the	solution	was	extracted	with	3	x100	mL	of	ethyl	acetate.	The	organic	
layers	were	combined	and	dried	over	anhydrous	sodium	sulfate.	The	solids	were	removed	by	
filtration	and	the	solution	was	concentrated	under	vacuum.	The	residue	was	filtered	initially	
with	a	silica	gel	column	eluting	with	ethyl	acetate/petroleum	ether	(7:10).	The	collected	
fractions	were	combined	and	concentrated	under	vacuum.	The	material	was	further	purified	by	
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Flash-Prep-HPLC	with	the	following	conditions	(IntelFlash-1):		Reverse-phase	column;	mobile	
phase,	water	(NH4HCO3,	10mmol/L)/acetonitrile	=	10%	increasing	to	water	(NH4HCO3,	10	
mmol/L)/acetonitrile	=	70%	within	50	min;	Detector,	UV	254	nm.	The	collected	fractions	were	
concentrated	under	vacuum	to	give	5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-
hydroxypiperidin-4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-
one	(7	g,	91%).							
																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														
High-resolution	mass	spectrometry	(HRMS):	(C24H23F4N7O3	–	expected	[M+H]+	534.18768,	
observed	[M+H]+	534.187770	(0.17	ppm).	Agilent	QTOF	6560	ESI+	mode.	Column:	Waters	
Acquity	UPLC	BEH	C18,	1.7	um,	2.1	x	50	mm.	Mobile	phase	A:	95%	Water/5%	Acetonitrile	with	
0.1%	Formic	Acid	/Mobile	phase	B:	95%	Acetonitrile/5%	Water	with	0.085%	Formic	Acid.		Flow	
rate:	20	mL/min.	Column	temperature:		35	°C.	Gradient:	5-100%	B	in	2.0	min,	hold	100%	to	2.2	
min.	LC	Flow	Rate:	0.6	mL/min.	UV	Wavelength:	220	nm	(Supplementary	Chemistry	Data	f).	
	
1H	NMR:		(300	MHz,	DMSO-d6)	δ	8.47	–	8.30	(m,	2H),	8.08	(dd,	J	=	9.0,	4.8	Hz,	2H),	7.81	(q,	J	=	
2.8	Hz,	1H),	7.44	(t,	J	=	8.8	Hz,	2H),	6.26	(td,	J	=	55.0,	3.6	Hz,	1H),	6.00-5.90	(m,	1H),	4.97	(s,	2H),	
4.15	–	3.96	(m,	3H),	3.70	(d,	J	=	13.6	Hz,	1H),	3.30	–	3.16	(m,	2H),	2.91	(ddd,	J	=	16.7,	11.7,	4.2	
Hz,	2H),	1.72	–	1.27	(m,	4H)	ppm	(Supplementary	Chemistry	Data g).	
19F	NMR	(376	MHz,	DMSO-d6)	δ	-131.12	(br	s,	1	F)	-127.80	-	-126.20	(m,	1	F)	-125.84	-	-	123.99	
(m,	1	F)	-114.84	(br	d,	J=2.63	Hz,	1	F)	ppm	(Supplementary	Chemistry	Data	h).			
	
13C	NMR	(101	MHz,	DMSO-d6)	δ	30.8,	34.4,	34.5,	35.1,	37.7,	53.5,	60.0,	69.5,	90.0,	107.1,	115.1,	
116.7,	124.1,	134.9,	136.7,	151.5,	152.2,	152.8,	159.8,	162.2,	164.5,	166.4	ppm	(Supplementary	
Chemistry	Data	i).			
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FT671	chiral	purification:	Preparative	supercritical	fluid	column	(SFC)	chromatography,	(R,R)-
WHELK-O1-Kromasil,	5cm	x	25cm	(5µM;	mobile	phase,	CO2	(50%),	isopropylalcohol:acetonitrile	
=	2:1(50%);	detector:	UV	220nm.		
First	eluting	isomer	(FT671):		5-([1-[(3S)-4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl]-4-
hydroxypiperidin-4-yl]methyl)-1-(4-fluorophenyl)-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one	
(retention	time:	5.78	min)	(3.0	g)	(Supplementary	Chemistry	Data j).		
Second	eluting	isomer:		5-([1-[(3R)-4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl]-4-
hydroxypiperidin-4-yl]methyl)-1-(4-fluorophenyl)-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one	
(retention	time:		7.74	min) (3.1	g)	(Supplementary	Chemistry	Data k).            
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